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Abstract 
Helicobacter pylori colonizes 50% of the world’s population, whereby glycoproteins and 
Lewis Y-containing lipopolysaccharides contribute to its pathogenesis. We investigated 
whether the HopE porin is glycosylated, if the glycan is Lewis Y, and if this is mediated by 
the putative oligosaccharide transferase HP0946 or the O-antigen ligase WaaL. Western 
blotting was performed on outer membranes with anti-HopE antibodies, anti-Lewis Y 
antibodies and fucose-binding BambL lectin to ascertain HopE glycosylation. We discovered 
that HopE is likely glycosylated by a non-Lewis Y fucose-containing glycan and neither 
HP0946 nor WaaL are the transferase. Additionally, we investigated HopE’s role in 
antibiotic susceptibility via Etest strips and disk diffusion method. By comparing sets of 
mutants for HopE, HP0946, and WaaL, we found that HopE does not affect antibiotic 
sensitivity, while eliminating HP0946 increases antibiotic sensitivity. Overall, this study 
presents HopE as a novel fucosylated glycoprotein and introduces a possible role for HP0946 
in antibiotic resistance. 
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1 Introduction 
 An introduction to Helicobacter pylori 
 Helicobacter pylori is a Gram-negative, microaerophilic bacterium with a spiral 
shape and several polar sheathed flagella1. Currently, it is well known that H. pylori can 
survive the harsh environment of the human stomach and can cause gastritis, peptic ulcer 
disease2 and gastric adenocarcinoma1. However, at the time of its discovery, the evidence 
that H. pylori could successfully colonize the stomach was controversial to the long-
standing belief that stress and lifestyle were the major factors in the manifestation of 
peptic ulcer disease3. 
 H. pylori was first isolated in 1982 by two Australian researchers, Barry Marshall 
and Robin Warren. Through drinking a culture of H. pylori, Dr. Marshall was able to 
demonstrate the association of H. pylori infection with gastritis and peptic ulcer disease  
when he developed gastritis after drinking the concoction4. Dr. Marshall’s experiment 
was revolutionary as it followed Koch’s postulates for the development of H. pylori-
associated gastritis and proved that the stomach was not a sterile environment, incapable 
of bacterial colonization4. As a result of this significant finding and the subsequent 
association with gastric cancer, Dr. Marshall and Dr. Warren were awarded the Nobel 
Prize in Physiology and Medicine in 2005 for their discovery of H. pylori’s involvement 
in chronic gastrointestinal disease. 
 
1.1.1 Clinical manifestation of H. pylori 
 Thirty-six years later, it is now recognized that H. pylori globally colonizes more 
than half of the world’s population5. Although present throughout the world, there is a 
large geographic variation in H. pylori’s prevalence based on socioeconomic factors and 
levels of hygiene6. The countries with the highest prevalence are Nigeria (87.7%), 
Portugal (86.4%), and Estonia (82.5%) whereas the countries with the lowest prevalence 
are Switzerland (18.9%), Denmark (22.1%), and New Zealand (24.0%). While the United 
States has a low prevalence of H. pylori (35.6%), its indigenous populations have a high 
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prevalence (74.8%)6. According to the Canadian Digestive Health Foundation, 10 million 
(27.5%) Canadians are infected with H. pylori, with roughly 75% of the First Nation 
communities infected. 
 Helicobacter pylori is the only microorganism that can cause gastric 
adenocarcinoma, and it is the first pathogen to be classified as a type 1 human carcinogen 
by the World Health Organization (WHO)5,7. Although only 1-3% of infected individuals 
develop gastric cancer8, this represents staggering numbers of affected individuals since 
H. pylori colonizes a large portion of the world’s population. This contributes to gastric 
cancer being the 5th cancer worldwide for prevalence9.  
 In order to treat H. pylori infections, suggested regimens include triple therapy or 
quadruple therapy10. Triple therapies involve the use of two antibiotics in combination 
with a proton pump inhibitor. However, due to the rise in antibiotic resistance, quadruple 
therapies are increasingly being prescribed. These therapies use a proton pump inhibitor, 
two antibiotics, a bismuth product and/or another antibiotic11. Proton pump inhibitors are 
used to suppress acid production and, in conjunction with the antibiotics, can help 
alleviate ulcer-related symptoms11. To date, antibiotic resistance and lack of patient 
tolerance has resulted in an increasing antibiotic treatment failure rate12. In fact, in 2017 
the WHO published its first ever list of antibiotic-resistant “priority pathogens”, a list of 
bacteria that pose the greatest threat to human health13. This list was created to guide and 
promote the research and development of new antibiotics for these priority pathogens. On 
the list, Helicobacter pylori was categorized as a “Priority 2: HIGH”, for its increasing 
drug resistance to clarithromycin, which is used in first line therapies for the treatment of 
H. pylori infections. Thus, it is mandatory to find novel avenues of treatment for 
individuals suffering from diseases caused by chronic H. pylori infections. 
 
 
4 
 
 The lipopolysaccharide (LPS)  
 The LPS layer is a key component of the outer membrane of H. pylori. The 
structure of H. pylori’s LPS is similar to the LPS of other Gram-negative bacteria and is 
composed of three domains: the hydrophobic lipid A domain embedded in the outer 
membrane, the core oligosaccharide, and the variable O-antigen polysaccharide14 (Figure 
1). This negatively charged structure plays a major role in providing a physical barrier 
against host defenses, detergents and antibiotics15.  
 Each domain of the LPS has a unique function. Lipid A serves as the membrane 
anchoring component and is usually an endotoxin responsible for certain pathologies 
during infections. Specifically, toll-like receptor 4 (TLR4), a receptor protein on animal 
cells, is activated by lipid A, inducing the release of proinflammatory cytokines via signal 
transduction and triggering the innate immune response16. If the immune response is 
strong enough, this activation can result in sepsis, leading to organ failure and death16. 
However, H. pylori has modified lipid A (one step of the pathway being the removal of 
the Kdo sugar via Kdo hydrolase, with the final step involving the removal of the 3’-O-
linked acyl chain resulting in a tetra-acylated lipid A from a hexa-acylated lipid A17,18) in 
order to minimize immune system activation, allowing for immune evasion and 
facilitating chronic infection17. The core oligosaccharide connects lipid A to the O-
antigen, and the O-antigen contributes to the antigenicity of the LPS molecule19. The LPS 
of H. pylori helps propagate this pathogen in two ways: creating Lewis antigens to 
facilitate host mimicry (see details below, section 1.2.2) and immune evasion20, and 
resistance to host cationic antimicrobial peptides (CAMPs) via the lipid A-core21.  
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Figure 1. Proposed LPS structure of H. pylori reference strain 26695.  
The three domains of the LPS are: the lipid A, the core oligosaccharide (divided into 
inner and outer core), and the O-antigen22. 
 
1.2.1 LPS biosynthesis 
 Characterizing the LPS biosynthesis pathway of H. pylori has not been an easy 
task. This is partially due to the genes involved in LPS biosynthesis being spread 
throughout the genome rather than organized into an operon like in most Gram-negative 
bacteria. However, in recent years there has been significant progress in our 
understanding of H. pylori’s LPS synthesis process. 
 There are three possible pathways for the biosynthesis of the O-antigen: the Wzy-
dependent pathway, the ABC-transporter-dependent pathway, and the synthase dependent 
pathway22, the first two being the most common. All three pathways commence in a 
similar fashion; WecA transfers a N-acetylglucosamine (GlcNAc) phosphate from UDP-
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GlcNAc to undecaprenyl pyrophosphate (Und-PP)23. Then the three pathways differ in 
terms of O-antigen creation and translocation22. It was expected that H. pylori uses a 
Wzy-dependent pathway, in which short O-antigen units are assembled and translocated 
to the periplasm via Wzx flippase, where they are polymerized by Wzy into the correct 
length with the help of Wzz and then ligated to the lipid A-core23. However, no homologs 
for wzx or coding sequences for the Wzy and Wzz enzymes existed in H. pylori23. 
 Surprisingly, H. pylori O-antigen synthesis follows a unique Wzk-dependent 
pathway (Figure 2), with Wzk being a translocase that enables the production of variable-
length O-antigens23. In this pathway, the Und-PP-GlcNAc resulting from WecA activity 
acts as an acceptor for the assembly of the O-antigen. Next, glycosyltransferases add 
alternating Gal and GlcNAc residues to create the O-antigen backbone23. Then, α1,3- 
fucosyltransferases FutA and FutB attach fucose molecules to select GlcNAc residues, 
creating Lewis X. The α1,2- fucosyltransferase FutC transfers fucose to the terminal Gal 
to generate Lewis Y24 (Figure 3). Notably, H. pylori displays a large diversity of Lewis X 
and Y expression on the LPS, with FutA and B acting as enzymatic rulers for 
fucosylation, only adding fucose to O-antigen polymers of specific lengths, based on the 
number of heptad repeats in the amino acid sequence of FutA and B24. This variability of 
the Lewis antigen expression pattern is likely in response to environmental changes, such 
as changes in pH25 and host blood group antigens, which would promote adaptation of 
certain individual isolates to their host environment and facilitate further immune 
evasion24. Once assembled, the O-antigen is translocated to the periplasm by the flippase 
Wzk and ligated to the lipid A-core by O-antigen ligase WaaL23. Interestingly, the Wzk 
enzyme was found to be dissimilar to other translocases but homologous to 
Campylobacter jejuni (CJ) PglK, a flippase of Und-PP-heptasaccharide used for protein 
N-glycosylation23,26.  
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Figure 2. Novel LPS biosynthesis pathway in H. pylori. 
LPS synthesis starts when WecA transfers GlcNAc (N-acetyl glucosamine) to UndP 
(undecaprenyl pyrophosphate). Next, glycosyltransferases (GalT and GlcNAcT) 
alternately add Gal and GlcNAc residues, producing the linear O chain backbone. Then, 
fucosyltransferases (FucTs) attach fucose residues on selected locations of the O-antigen 
backbone, generating Lewis antigens. The flippase Wzk transfers this O-antigen to the 
periplasm, where it is attached onto the lipid A-core via the O-antigen ligase WaaL. Once 
the LPS molecule is assembled, it can be transported to the outer membrane by Lpt 
(lipopolysaccharide transport) proteins (a transenvelope complex)23. 
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Figure 3. Enhanced view of a Lewis Y LPS structure.  
The Lewis Y O-antigen is formed by the attachment of fucose to the terminal Gal in an α-
1,2 linkage and to the preceding GlcNAc in an α-1,3 linkage. The R refers to the rest of 
the molecule. Adapted from Hug et al.23 and expanded upon (Creuzenet lab). 
 
1.2.2 Lewis O-antigens and host mimicry 
 As introduced above, the LPS of H. pylori is unique in that it expresses Lewis 
Blood Group antigens and presents them on the O-antigen domain20. These are 
carbohydrates that are commonly associated with host monocytes, macrophages, 
granulocytes and gastric epithelial cells20. Predominantly, 80-90% of H. pylori strains 
produce type 2 blood group antigens Lewis X and Lewis Y on the LPS27,28. The pathogen 
also expresses type 1 blood group antigens Lewis A, Lewis B, Lewis C and H-antigens at 
a lower frequency29. Molecular mimicry by these antigens allows for H. pylori’s 
protection against recognition as a foreign invader and facilitates successful immune 
evasion20. However, upon recognition of the pathogen over time, this mimicry also 
causes an autoimmune response, leading to inflammation and tissue damage20.  
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1.2.3 Phase variation 
 H. pylori is known to be very genetically diverse30. One method of increasing 
diversity is phase variation (or antigenic variation), in which surface epitopes, like those 
presented on the LPS, are reversibly switched on-and-off 31. A proposed mechanism for 
phase variation is strand slippage during DNA replication in regions with homopolymeric 
tracts or oligonucleotide repeats31. The resulting products of phase variation create a 
microorganism that is more versatile and better able to cope in varying environmental 
conditions31. Switching on certain genes may allow this microorganism to adhere better 
to mucosal cells or decrease antigenicity and recognition by antibodies; switching off 
certain other genes may result in the reverse effect31. It has been determined that 
fucosyltransferases involved in Lewis X and Y antigen assembly undergo phase 
variation31, due to their homopolymeric tract which is denoted as the frame shifting 
region in Figure 4.  
 In fact, there are a total of 27 predicted phase variable genes in H. pylori, several 
of them from the Hop outer membrane family. This includes porins HopC and HopD, 
HopM, and adhesin HopZ. In general, phase variation could explain the differences in 
isolates found within different human hosts. 
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Figure 4. H. pylori fucosyltransferases responsible for Lewis X and Y antigens. 
A) Lewis antigen structures and the pathway with enzymes involved in their synthesis. B) 
FutA and B (α1,3- fucosyltransferases), indicating frame shifting in the 5’ polyC tract, 
with the 7 amino acid heptad region determining the size of the O-antigen polymers that 
become fucosylated. C) FutC (α1,2- fucosyltransferase), frame shifting in the middle of 
the gene resulting in variable expression of Lewis glycosylation24. 
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 Helicobacter pylori’s outer membrane proteins (OMPs) 
 Through bioinformatics analysis of H. pylori J99 and 26695, five paralogous gene 
families of outer membrane proteins (OMPs) were identified, with a total of ~64 
members32. The largest family is comprised of 21 Hop (H. pylori OMP) proteins and 12 
Hor (Hop related) proteins. Members of the Hop family are grouped together due to their 
shared or identical amino acid sequences at the N- and C- termini32. Family 2 contains 8 
Hof (for Helicobacter OMP family) proteins, characterized by their similar molecular 
masses and hydrophobic C-terminal sequence motif present in most OMPs, and family 3 
has 4 Hom (for Helicobacter outer membrane) proteins with conserved N- and C-termini 
and the C-terminal hydrophobic motif32. The last two families are characterized due to 
their homology to iron-regulated OMPs found in other bacteria, labeled FecA-like 
(similar to Escherichia coli’s ferric citrate receptor) and FecB-like (similarity to 
Neisseria spp.’s major iron-regulated OMP). Family 4 is comprised of iron-regulated 
OMPs (6 members) and family 5 includes efflux pump OMPs (3 members). The 
remaining OMPs are not members of any families (~10 members).  
 Five Hop members (HopA-E) from strain 26695 are characterized as porins33, 
with some Hop proteins also functioning as adhesins (such as BabA and BabB)34. 
Specifically, the porin HopE (31 kDa), that is the focus of this thesis, is the smallest of 
these proteins and can form trimers (90 kDa)33. Like other porins, HopE is predicted to be 
a β- barrel structure, containing 16 strands with alternating hydrophobic and hydrophilic 
residues35. Forming atypically large water-filled channels for a porin, HopE has no 
specific binding sites and no preference for anions or cations, implying that it is a major 
nonspecific porin of H. pylori due to its lack of substrate specificity to ions33.  
 
 
12 
 
 H. pylori’s inner membrane proteins 
Unlike outer membrane proteins, inner membrane proteins have not currently been 
characterized and quantified to the same extent in H. pylori. However, this section will 
discuss some notable inner membrane proteins.  
 Several of the proteins involved in LPS biosynthesis are localized within the inner 
membrane, such as the aforementioned WecA, the fucosyltransferases FutA and C, the 
O-antigen flippase Wzk, and the O-antigen ligase WaaL. Another essential inner 
membrane protein is UreI, part of the urease gene cluster of seven open reading frames 
ureABIEFGH, and survival of H. pylori in the acidic gastric environment is contingent on 
the expression of this inner membrane urea channel36. This channel conveys the gastric 
urea to the cytoplasmic urease, where it is hydrolyzed into carbon dioxide and ammonia, 
buffering the periplasm to a pH of 6.137.  
 Additionally, several putative paralogous inner membrane efflux pumps have also 
been identified: HefC, HefF and HefI. It is suggested that the efflux pump HefC may play 
a critical role in pumping out bile salts that it encounters in vivo, specifically in the 
duodenum, to prevent the antimicrobial effects of the substance38. Currently, the 
functions of HefF and HefI are unknown. 
 Lastly, HP0946 is a protein of interest in this thesis. Through in silico analysis 
conducted in the lab, it is a predicted inner membrane protein with 13-14 transmembrane 
domains (depending on the software) and is currently annotated as a sodium-proton 
antiporter. Additionally, our lab discovered that HP0946 shares some similarity to a well-
known oligosaccharide transferase in C. jejuni, PglB, an enzyme that is involved in 
protein glycosylation. HP0946 is also predicted to have 2-3 large periplasmic loops that 
may interact with substrates (which can be either proteins or glycans). As such, it would 
be of interest to further investigate the function of HP0946 and determine if there is any 
connection to the LPS biosynthesis pathway, potentially by interacting with the Lewis 
substrate and leading to glycosylation of protein(s) with this substrate. 
13 
 
 Protein glycosylation 
 Protein glycosylation is characterized as the modification of proteins through 
covalent attachment of carbohydrates39. Initially, it was thought that protein glycosylation 
existed only in eukaryotes, however it is now well established that protein glycosylation 
occurs in prokaryotes and archaea as well. These modifications are critical for a wide 
range of biological processes, such as controlling protein folding and protein stability40, 
regulating intracellular trafficking, modulating enzyme and hormone activities, 
participation in cell-cell interactions, and acting as cell surface receptors41.  
 There are two main types of protein glycosylation: N-linked and O-linked. N-
glycosylation occurs via linkage of a glycan (such as GlcNAc or other) to the nitrogen in 
the amido group of asparagine, whereas O-glycosylation occurs when a glycan (i.e. N-
acetylgalactosamine, GalNAc or other) is attached to the oxygen in the hydroxyl group in 
either serine or threonine42.  
 The sites at which glycosylation takes place depends on the specific sequence of 
amino acids adjacent to either asparagine (Asn), serine (Ser) or threonine (Thr)42. The 
consensus sequence for N-glycosylation is either Asn-X-Thr/Ser (with X being any 
amino acid except proline)42. This is a well conserved sequence in eukaryotes, however 
prokaryotes likely have an extension of this glycosylation sequence. Bacteria such as 
Campylobacter jejuni require an extended glycosylation sequence, which is as follows: 
Asp/Glu-Y-Asn-X-Ser/Thr (where X and Y are not proline)43. No widespread consensus 
sequence has been determined for O-glycosylation42, however one lab was able to 
determine the conserved sequence in intestinal Bacteroides species, Bacteroides fragilis, 
as being Asp-Ser/Thr-Ala/Ile/Val/Met/Thr (the last amino acid must contain either one or 
more methyl groups)44. To date, only Campylobacter jejuni has been found to carry both 
N- and O-protein glycosylation pathways45. 
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1.5.1 Protein glycosylation in eukaryotes 
 First discovered in eukaryotes, it is now predicted that more than two-thirds of 
eukaryotic proteins undergo protein glycosylation46. Regardless of the eukaryote, the 
biosynthetic machinery responsible for this modification follows a similar progression. 
 The eukaryotic N-glycosylation pathway starts with the assembly of the glycan in 
the cytoplasm of the endoplasmic reticulum (ER) and is mediated by the membrane-
embedded dolichol pyrophosphate lipid carrier. The glycan is extended through the 
addition of sugar molecules by embedded glycosyltransferases in a step-wise manner to 
form the precursor oligosaccharide. Next, the glycan is translocated across the membrane 
to the ER lumen by a currently unknown flippase protein, where the oligosaccharide 
decoration is resumed by more glycosyltransferases on the lumen side and results in the 
production of a conserved tetradecasaccharide (Glc3Man9GlcNAc2) core oligosaccharide. 
This final oligosaccharide is then transferred en bloc to the target protein by an N-
oligosaccharide transferase (N-OST)47.   
 Comparatively, the process of eukaryotic O-glycosylation is much more variable; 
currently, no dedicated O-glycosylation pathway has been identified. Although most O-
glycosylation occurs in the Golgi apparatus, some O-glycosylation has been found to be 
initiated in the ER. O-glycosylation begins with the addition of monosaccharide 
(commonly N-acetyl-galactosamine, GalNAc) to the protein by a glycosyltransferase, 
followed by sequential addition of more sugars (such as fucose, mannose, and glucose) to 
form the final glycan48. Regardless of the discrepancies, both forms of eukaryotic 
glycosylation contribute to the wide range of protein diversity. 
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1.5.2 Protein glycosylation in prokaryotes 
 Since the discovery of surface layer (S-layer) glycoproteins in a Gram-negative 
halophile, Halobacterium salinarium in the 1970s49, it has been well established that 
prokaryotes also go through this modification, such as C. jejuni50 and H. pylori51. In fact, 
the first N-linked protein glycosylation was discovered in C. jejuni52.  
 More than 60 N-glycoproteins have been identified in C. jejuni53. As the model 
system for bacterial N-glycosylation, glycosylation initiates when a heptasaccharide is 
assembled (one sugar at a time) to an undecaprenyl pyrophosphate on the cytoplasmic 
side of the inner membrane. The assembled lipid-linked oligosaccharide is then flipped 
across the inner membrane to the periplasm by an ATP-dependent flippase, PglK54, 
similar to eukaryotic N-glycosylation. Then, an oligosaccharide transferase (OST), 
PglB55, transfers the glycan to an asparagine residue on the acceptor protein. Mutations 
within this pathway in C. jejuni have been shown to reduce chicken colonization56, 
adherence ability, and diminish the ability to invade intestinal epithelial cells in vitro57.  
 Similar to N-glycosylation, O-glycosylation has been described in several bacteria 
and archaea. O-glycosylation is well known to occur on bacterial surface appendages, 
such as flagella and pili. Focusing on C. jejuni again, O-linked glycan modification of the 
flagella is necessary for flagellum assembly, and can affect auto-agglutination, biofilm 
formation and colonization of the gastrointestinal tract58. The O-linked glycans on the 
flagellar proteins can constitute up to 10% of the protein mass50. Predominantly, the O-
glycans attached to the flagellum are pseudaminic acid (PA) or legionomic acid 
derivatives59,60. 
 Unlike the en bloc transfer of glycans in N-glycosylation pathways, flagellin O-
glycosylation mainly occurs in a sequential pattern. In this case, glycosyltransferases 
sequentially transfer monosaccharides to the target protein. Once completed, the 
glycosylated flagellin monomers are secreted to the tip of the growing flagellin unit. This 
form of O-glycosylation is OST-independent and is generally used to glycosylate 
flagellins and non-pilus adhesins such as autotransporters61. 
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 Similar to the N-glycosylation pathway described in C. jejuni, OST-dependent O-
glycosylation is used to glycosylate the type IV pilus of Neisseria gonorrhoeae and 
Neisseria meningitidis. This pathway is initiated when the glycosyltransferase attaches a 
monosaccharide to the undecaprenolphosphate (Und-P) lipid carrier located on the inner 
side of the plasma membrane. Then, glycosyltransferases attach more monosaccharides to 
this precursor. Once completed, the Und-P linked glycan is flipped to the periplasm and 
an OST transfers this glycan to the target protein62. In addition to being similar to the N-
glycosylation pathway, this general O-glycosylation also has similarities to the Wzy-
dependent pathway involved in the production of LPS O-antigen synthesis23. Overall, O-
glycosylation is widespread and not the rare event it was previously perceived to be. 
However, there are still many enzymes in this pathway that have not been identified and 
characterized. 
 
1.5.2.1 Outer membrane protein glycosylation in prokaryotes 
 Currently, two bacterial porins have been identified as glycoproteins. Previous 
research regarding a porin in Campylobacter jejuni, major outer membrane protein 
(MOMP), showed that the MOMP is O-glycosylated with a glycan moiety containing one 
galactose and three GalNAc residues at T268, which is in a surface exposed loop, with 
this glycosylation resulting in a conformational change of MOMP63. The glycosylation of 
this porin either directly or indirectly promoted cell-to-cell binding, biofilm formation, 
adhesion to Caco-2 cells, and was necessary for C. jejuni’s optimal colonization of 
chickens63.  
 The second porin, OprD of Pseudomonas aeruginosa, is a β-barrel shaped 
channel-forming porin which uptakes basic amino acids, peptides and β-lactam 
antibiotics. It is highly sialylated, resulting in lower penetration of β-lactam antibiotics 
through this porin, indicating this may be a novel mechanism of drug resistance64. Thus, 
it is possible that glycosylation of HopE may also contribute to antibiotic resistance. 
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 Helicobacter pylori and protein glycosylation 
 To date, characterizing novel protein glycosylation pathways in H. pylori and its 
role on protein function has been elusive. Currently, it is known that flagellins FlaA and 
FlaB that comprise of the flagellar filaments are O-glycosylated with pseudaminic acid, 
which is essential for the production of the flagellum and virulence of the pathogen51.  
 Interestingly, mounting evidence from three individual labs suggests a connection 
between flagellin glycosylation and LPS O-antigen biosynthesis in Aeromonas caviae65, 
Helicobacter pylori66, and Pseudomonas aeruginosa67. Specifically, in H. pylori, the 
FlaA1 enzyme is involved in the pseudaminic acid synthesis pathway for the 
glycosylation of flagella51,68. This enzyme was implicated in functionally linking the 
control of LPS biosynthesis and flagellum production, with protein glycosylation being 
the underlying mechanism for this interconnection66. Further evidence for a link in the 
two machineries is identified by the aforementioned flippase Wzk, that is homologous to 
Campylobacter jejuni’s PglK enzyme that is involved in N-glycosylation26. The last piece 
of evidence stems from our unpublished lab data, in which a connection was discovered 
between two proteins of interest in this thesis: the O-antigen ligase WaaL, HP0946 (a 
putative Lewis Y oligosaccharide transferase) and FlaA1 via RT-qPCR. HP0946 
transcription expression levels were upregulated in mutants that tend to increase Lewis Y 
availability: 7-fold in a waaL mutant that is unable to attach O-units for LPS assembly 
and 10-fold in a flaA1 mutant that cannot utilize Und-PP-GlcNAc, a component of Lewis 
antigen synthesis66.   
 Previously, the Creuzenet lab determined that the pseudaminic acid pathway is 
not limited to H. pylori’s flagellin production, but also targets proteins involved with 
virulence factor production, such as LPS and urease45. The data also identified several 
non-flagellar glycoproteins using glyco-specific stains, digoxigenin-3-O-succinly-ε-
aminocaproic acid hydrazide (DIG) labelling and mass spectrometry (MS)45. This idea 
that non-flagellar proteins are glycosylated in H. pylori had also been proposed 
concurrently by another lab based on global metabolic profiling, but in that study the 
glycoprotein (GP) candidates had not been isolated or characterized69. In the Creuzenet 
lab, identification was conducted on 9 GP candidates, which were the most abundant. 
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One of the GP candidates was determined to be catalase, whose glycosylation had never 
been reported before. The other GP candidates were presumed to be linked to LPS 
biosynthetic enzymes, since PA mutants expressed altered or no O-antigens45. Through 
further research with wild-type and PA mutants, it was concluded that there may be 
several glycosylation pathways in H. pylori45.  
 Evidence of glycosylation of non-flagellar proteins in H. pylori was further 
corroborated by another lab. Using a combination of metabolic glycan labelling 
(supplementing the strain with peracylated N-azidoacetylglucosamine, Ac4GlcNaz, 
leading to labelling of the N-linked and O-linked glycoproteins with azide), MS analysis, 
and Western blotting, this lab was able to identify the existence of 125 putative GPs in H. 
pylori70. These results revealed that GPs are abundant and widespread in H. pylori, 
existing on the cell surface, inner and outer membranes, and within the periplasm and 
cytoplasm70. This distribution suggests that protein glycosylation may be an essential 
process of H. pylori’s physiology, with intracellular glycans potentially being involved in 
stabilizing proteins and extracellular glycans stabilizing proteins and mediating host-cell 
interactions70.  
 While these 125 proteins comprise those previously identified in the Creuzenet 
lab, they do not comprise the outer membrane protein HopE that is the focus of this 
study. One reason for this would be the nature of HopE glycosylation. Based on the sugar 
chemistry of metabolic labelling, the GlcNac to be labelled would have to be on the base 
of the polysaccharide structure. Although GlcNac in H. pylori is the initiating (base) 
sugar in the process of LPS synthesis (and HopE glycosylation may happen by 
attachment of this LPS O-antigen to the HopE protein), OSTs are usually specific for the 
motif they recognize and transfer to the protein. Thus, the Lewis Y OST may not transfer 
this single initiating base GlcNac, and there would be no guarantee that metabolic 
labelling would aid in the identification of HopE. 
 Recently, using biotin-hydrazide labeling, anti-Lewis Western blotting, and silver 
staining of outer membranes, our lab discovered that H. pylori strain NCTC 11637 
contained a ~31 kDa Lewis Y glycoprotein. MS and enrichment by lectin affinity 
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chromatography potentially identified this protein as the HopE porin that may be 
glycosylated by a Lewis Y antigen. To confirm this, a hopE knockout mutant was 
constructed, and anti-Lewis Y Western blotting of the outer membranes determined that 
this ~31 kDa protein was present in the wild-type but absent in the knockout mutant. The 
MS data also identified a putative glycopeptide that partially matched the amino acid 
sequence of HopE, and which had 3 potential glycosylation sites: O-glycosylation on a 
serine or threonine, and a N-glycosylation consensus sequence reading as Asn-Ala-Thr. 
Modelling by Dr. Creuzenet (using the program Swiss-Prot against P. aeruginosa’s 
OprH) indicated that this putative glycopeptide was localized on the surface of the outer 
membrane, implicating its possible role in host mimicry, immune evasion, or adhesion to 
host tissues (Figure 5).  
   
 
Figure 5. Three-dimensional model of HopE.  
HopE is likely glycosylated on the purple surface exposed loop as per preliminary mass 
spectrometry data. Approximate boundaries of the hydrophobic regions of the proteins 
predicted to be embedded in the outer membrane are represented by horizontal lines. 
Modelled by Dr. Creuzenet. 
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 Hypothesis and objectives 
Based on the above evidence, we propose that: The HopE porin in H. pylori plays a role 
in antibiotic susceptibility, which may be influenced by HopE glycosylation with a Lewis 
O-antigen transferred by the putative oligosaccharide transferase HP0946. Collectively, 
this contributes to the pathogen’s virulence. 
To address this hypothesis, we have three objectives: 
1) Optimize the detection of HopE using anti-HopE antibodies to determine whether 
HopE is glycosylated, via anti-Lewis Western blotting.  
2) Investigate the role of the Lewis oligosaccharide transferase HP0946 in potential HopE 
glycosylation and determine its connection to LPS synthesis.  
3) Elucidate the functional impact of HopE and its putative Lewis glycosylation in regard 
to antibiotic resistance/susceptibility.  
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2 Materials and methods 
 Bacterial strains and growth conditions 
 All Helicobacter pylori NCTC 11637 strains were grown under microaerobic 
conditions (5% O2, 10% CO2, and 85% N2) and 90% humidity in a tri-gas incubator 
(NuAire) for 48 hours on Columbia agar (Fisher Scientific) plates supplemented with 
7.5% sheep blood (Cedarlane), 0.05 µg/mL sodium pyruvate (BioShop), 5 µg/mL 
trimethoprim (Sigma-Aldrich), 10 µg/mL vancomycin (Bio Basic), and 4 µg/mL 
amphotericin B (Bio Basic); these are considered the “background” antibiotics. When 
growing knockout strains, the agar was supplemented for selection with 5 µg/mL of 
kanamycin (Bio Basic) and/or 12 µg/mL of chloramphenicol (Fisher Scientific). H. pylori 
cells were stored as freezer stocks kept at -80°C in brain heart infusion yeast extract 
(BHI-YE) media (EMD and Fisher Scientific) with 25% glycerol (Fisher Scientific) and 
the appropriate antibiotics/supplement. After initial revival from a loopful of freezer 
stock onto Columbia agar plates, the cells were spread onto a new plate via sterile loop 
and grown for 48 hours. The confluent lawn was resuspended in BHI-YE broth with no 
supplement or antibiotics and normalized to an OD600 of 0.2 before being spread to new 
Columbia agar plates with no selection antibiotics via sterile cotton swabs. After 48 
hours, the cells were harvested to an OD600 of 0.5 before downstream phenotypic 
analyses. Table 1 shows the list of strains used in this study. 
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Table 1. Helicobacter pylori strains used. 
Strain Gene(s) disrupted Antibiotic 
cassette 
Made by 
VJ WT None --- Used by V. Somalinga 
VJ ΔhopE  hopE Chloramphenicol K. Yogendirarajah  
(in this study) 
MK WT None --- Used by M. Khodai-
Kalaki 
BO ΔhopE  hopE Chloramphenicol B. Oickle 
Δ946  946 Kanamycin J. Denomme 
ΔhopE/Δ946 hopE and 946 Chloramphenicol 
and kanamycin 
K. Yogendirarajah 
(in this study) 
ΔwaaL  waaL Kanamycin A. Merkx-Jacques 
ΔhopE/ΔwaaL hopE and waaL Chloramphenicol 
and kanamycin 
K. Yogendirarajah 
(in this study) 
 
 Escherichia coli DH5α cells were grown in Luria Bertani (LB) broth (BioShop) in 
a 37°C shaking incubator at 133 rpm (New Brunswick Scientific) in standard 
atmospheric conditions. The broth was supplemented with 100 µg/mL ampicillin (Bio 
Basic) and/or selection antibiotics of either 34 µg/mL chloramphenicol or 30 µg/mL 
kanamycin. 
 
  Membrane fractionation by differential solubilization 
 H. pylori cells were revived and subsequently grown and expanded to 20 plates of 
confluent growth. Cells were re-suspended in 5 ml of 0.85% saline and lysed in a cell 
disrupter (Constant Systems LTD IS6/40/BA/AA model) at 25,000 psi. Cellular debris 
and unlysed cells were pelleted by centrifugation at 5,000 g for 20 min. The supernatant 
was removed and ultracentrifuged for 1 hour at 100,000 g at 4°C to pellet membrane 
24 
 
proteins (Optima-XL 100K ultracentrifuge, Beckman Coulter, TLA 110 rotor). The 
recovered total membrane pellet was resuspended in 1 mL of 0.85% saline and 
ultracentrifuged again for 1 hour under the same conditions as previously mentioned. 
Then, the total membrane pellet was resuspended in 1 mL of solubilization buffer (50 
mM sodium phosphate, 300 mM NaCl, pH 7.2) containing 1% w/v N-laurylsarcosine 
(Sigma-Aldrich) and mixed on a nutator for 1 hour at room temperature and overnight at 
4°C. The outer membrane was pelleted from the inner membrane via ultracentrifugation 
at 100,000 g for 1 h at 4⁰C. The outer membrane pellet was mixed again with 
solubilization buffer to further remove any leftover non-outer membrane components. 
The final clean outer membrane pellet was resuspended in PBS (50 mM sodium 
phosphate, 300 mM NaCl, pH 7.2) for protein analysis via SDS-PAGE. 
 
  Proteinase K digestion  
 For experiments that required complete protein degradation, outer membrane and 
total membrane protein samples were digested with Proteinase K (PK). To 120 µL of 
total protein samples, 5 µL of 20 mg/mL PK (BioShop) was added, while 30 µL of outer 
membrane samples were supplemented with 2 µL of 20 mg/mL PK. Samples were 
incubated at 60°C overnight to ensure completed digestion. 
 
 Western blotting and SDS-PAGE analysis  
 Bacterial cells were denatured with 1X SDS loading buffer (0.625 M Tris, 2% 
SDS, 2% β-mercaptoethanol, 10% glycerol, 0.002% bromophenol blue, pH 6.8) and 
incubated for 5 min at 100°C. The proteins were separated by SDS polyacrylamide gels 
in the Laemmli system (Bio-Rad mini gel system). The gels used varied depending on the 
application and included 12% bis-acrylamide gels (made in lab), bis-acrylamide step-
wise gels (12% in the bottom third of the gel, 15% in the middle and 20% at the top; 
made in lab), and pre-cast gradient gels (4-20% bis-acrylamide, Bio-Rad). Lab-made gels 
were electrophoresed at 30 mA, while pre-cast gels were run at 250 V in 1X tris-glycine 
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buffer (0.025 M Tris, 0.192 M glycine, 0.1% SDS, pH 8.3). Proteins and carbohydrates 
were visualized either via silver staining or Western blotting. Proteins were occasionally 
also visualized by Coomassie blue staining (10% acetic acid, 25% ethanol, 0.001% w/v 
Brilliant Blue R-250 (Bio-Rad). Antibodies, lectin and Western blotting conditions used 
are explained in Table 2. 
 For Western blotting, proteins were transferred to nitrocellulose membrane (Bio-
Rad) via wet transfer for 45 min at 180 mA in cold tris-glycine transfer buffer (25 mM 
Tris, 192 mM glycine, 10% methanol, pH 8.3). After transfer, the proteins on the 
membrane were visualized with Ponceau S stain (0.1% w/v Ponceau S (Sigma-Aldrich) 
and 1% v/v acetic acid) for 2 min and washed with milliQ water. The membrane was 
blocked for 1 hour with 10% skim milk with gentle shaking on the gel surfer (Diamed). 
All further steps were performed with this gentle shaking. The membrane was then 
washed twice with phosphate buffered saline (PBS) buffer (137 mM NaCl, 2.7 mM KCl, 
8 mM Na2HPO4, 1.46 mM KH2PO4, pH 7.2) supplemented with 0.05% Tween-20 (USB 
Corporation), and once in PBS buffer for 10 min each. Then, the membranes were 
incubated with primary antibody for 1 hour. After incubation, the membrane was washed 
as previously mentioned, then incubated with secondary antibody for 35 min in the dark. 
The membrane was washed in the dark as stated above. Protein or LPS was visualized 
using the Odyssey CLx imaging system (Li-Cor) at the wavelengths mentioned in Table 
2. 
 Western blots were performed to screen aliquots of rabbit anti-HopE antibody 
sera from different bleeds at different concentrations to determine optimal conditions for 
future Western blotting. The outer membranes WT and ΔhopE samples were separated by 
step-wise gels (with a single large well) and transferred to nitrocellulose membranes as 
stated above. After transfer and Ponceau S staining of total protein content, the 
membranes were cut length-wise into 7 identical strips and each strip was individually 
blotted with the different bleeds (bleed #2, #3, #4) and the pre-immune serum. The strips 
were then washed, blotted with the secondary antibody, and imaged as previously 
mentioned. 
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Table 2. Western blotting reagents used. 
Epitope detected Primary 
antibody/lectin 
Secondary 
antibody 
Wavelength 
detection (nm) 
HopE Anti-HopE (1/200) 
rabbit (ProSci) 
[Custom ordered] 
Goat anti-rabbit 
IRDye (1/5000)   
(Li-Cor) 
800 
Lewis Y Anti-Lewis Y 
(1/100) mouse 
(Calbiochem) 
Anti-mouse 
(1/5000) goat 
AlexaFluoro 680 
(Invitrogen) 
700 
Fucose BambL lectin 
(biotinylated by the 
Creuzenet lab) 
Streptavidin 
conjugated 
AlexaFluoro 680 
(Invitrogen) 1µg/mL 
700 
 
 Silver staining of carbohydrates 
 The following silver staining protocol was created by Fomsgaard et al71. Briefly, 
carbohydrates were first separated on an SDS-PAGE and then oxidized in a solution of 
0.7% w/v periodic acid, 40% v/v ethanol and 5% v/v acetic acid in milliQ water with 
shaking for 20 min. The oxidation was followed by five washes over 15 min in milliQ 
water. The gel was then stained with silver nitrate (Fisher Scientific) in a staining 
solution (0.19% v/v 10 N NaOH, 1.3% v/v ammonium hydroxide, 0.7% w/v silver 
nitrate). Gels were stained for 10 min, followed by five washes over 15 min in milliQ 
water. Following the wash, the gels were developed using 0.005% w/v citric acid and 
0.05% v/v formaldehyde (37%) in milliQ water until bands became visible. The gels 
were then washed several times with milliQ water and scanned. 
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 Chromosomal DNA extraction from H. pylori 
 Chromosomal DNA was extracted from total cell pellets using the 
cetyltrimethylammonium bromide (CTAB) buffer (100 mM Tris-HCl, 1.4 M NaCl, 0.02 
M EDTA, 1% w/v CTAB (BioBasic), pH 8.8) method. To the cell pellet, 500 µL of 1% 
CTAB buffer and 500 µL of phenol:chloroform:isoamyl alcohol (25:24:1 v/v/v) was 
added and vortexed to mix the solutions until an emulsion formed. This mixture was 
centrifuged at 13,000 g for 5 min. The top aqueous layer was extracted and 500 µL of 
chloroform-isoamyl alcohol (24:1) was added and centrifuged at 13,000 g for 5 min to 
remove residual phenol. The top aqueous phase was recovered, and the DNA was 
precipitated by adding 0.08 volume of chilled 3 M potassium acetate and 0.54 volume of 
chilled isopropanol. The tubes with the mixture were inverted 30 times and incubated on 
ice for 35 min. The DNA was pelleted by centrifugation at 13,000 g for 10 min at 4°C. 
The DNA pellet was washed once with cold 100% ethanol, centrifuged as before, and 
washed once again with cold 70% ethanol and air dried. The final DNA pellet was 
resuspended in 50 µL of autoclaved TE buffer (50 mM Tris-HCl, 2 mM EDTA, pH 8) 
and stored at 4°C. 
 
 Agarose gel electrophoresis 
 All PCR products were analyzed using 0.7% agarose gel prepared in TAE buffer 
(40 mM Tris-acetate, 1 mM EDTA, pH 8.0). Samples were mixed with DNA loading 
buffer (1X TAE buffer, 12.5% glycerol, 0.0025% bromophenol blue) before loading and 
compared to a 1 kb DNA ladder standard (Invitrogen).  Ten µL of ethidium bromide 
(Invitrogen) were added to the gel tank before running the gel. Gel electrophoresis was 
performed at 80 V for 30 min. DNA bands were visualized using UV light (254 nm) in 
the Quantity One Chemidoc XRS system. 
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 Transformation of pUC18/706KO into H. pylori 
NCTC11637 strains 
 The appropriate H. pylori strain was grown under microaerobic conditions as 
described above and the cells were harvested into BHI-YE broth, pelleted at 4,000 rpm 
for 10 minutes and washed twice in 0.85% saline, with centrifugation steps in between. 
The cells were then adjusted to an OD600 of 0.5 in 0.85% saline. A total of 20 µg of 
plasmid DNA was added to the cells to a final volume of 100 µL. A negative 
transformation control consisted of 100 µL of cells with no plasmid incorporated. The 
transformation mixtures were spotted onto Columbia agar plates supplemented with 7.5% 
sheep blood, containing the antibiotics necessary for the original strain (WT or mutant 
knockout) and cells were allowed to recover for 8 hours under microaerobic conditions at 
37°C. The spots were resuspended in BHI-YE broth and plated onto Columbia agar 
plates containing the appropriate antibiotics for selection using glass beads. Plating onto 
Columbia agar plates with no antibiotics, to ensure viability after transformation, was 
also done in parallel. These plates were grown for 5-7 days under microaerobic 
conditions at 37°C until colonies were observed.  
 
 Minimum Inhibitory Concentration (MIC) E-strips  
 As mentioned in section 2.1, once the strains have been diluted to an OD600 of 0.5 
in 0.85% saline, the suspension was spread with a sterile cotton swab onto Columbia agar 
plates (with 7.5% sheep’s blood and no background/selection antibiotics or pyruvate). 
Without re-dipping in the suspension, the plates were swabbed twice more after rotating 
the plate 120° each time. After letting the plates dry for 2 min at atmosphere conditions, 
the antibiotic E-test strip (Oxoid) was removed from its packet with clean forceps and 
gently placed into the centre of each plate, being careful not to introduce bubbles between 
the strip and the agar. Plates were incubated in microaerobic conditions in the 37°C 
incubator for 48 hours. After incubation, the MIC was read off the strip.  
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2.10 Disk diffusion assay 
 The antibiotic disks used in this assay were made in lab. Using a hole puncher to 
create the disk shape, Bio-Dot SF filter paper (Bio-Rad) was cut and sterilized under UV 
light. Once the appropriate concentrations of the clarithromycin antibiotic were 
calculated, 10 uL of the solution was added onto the disks, dried, and stored at 4°C. 
 H. pylori strains were adjusted to an OD600 of 0.5 in 0.85% saline. The plates 
were swabbed as per section 2.8 above and then left to dry for 2 min at atmosphere 
conditions. Once dried, the plate was divided in half (one half per antibiotic concentration 
to be tested) and the disks were placed with clean forceps in the center of the appropriate 
section of the plate. After incubating the plate for 48 hours in microaerobic conditions at 
37°C, the diameter of the zone of inhibition was measured using a ruler (in millimetres). 
 
2.11 Immunoprecipitation of HopE 
 HopE polyclonal IgG antibodies immobilized to protein G agarose beads (Roche 
Diagnostics) were used to pulldown and purify the HopE protein from the outer 
membrane protein sample.  
 To prepare for binding, 400 µL of the beads were washed with 0.1 M sodium 
phosphate buffer (PB) at pH 7.4, and were incubated with 100 µL anti-HopE rabbit 
serum and 320 µL of 0.1 M PB at 4°C with agitation for 30 min. The beads were then 
washed three times with 0.1 M PB. The protein G immobilized antibodies were washed 
with 0.2 M triethanolamine (Sigma-Aldrich) buffer, which allows for the optimal 
crosslinking activity of dimethyl pimelimidate (DMP). Cross-linking buffer containing 
0.2 M triethanolamine and 22 mM of DMP (Sigma-Aldrich) was then added and allowed 
to incubate for 45 min at room temperature. Next, 0.1 M ethanolamine (Fisher Scientific) 
blocking buffer (pH 7.4) was added to quench the cross-linking reaction, and the solution 
was left for 1 hour at room temperature with agitation to incubate. Finally, 1 mL of 0.1 M 
glycine-HCl (pH 2.5) elution buffer was used to remove any non-cross-linked IgG 
molecules from the protein G beads and immediately washed with 0.1 M PB after the 
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beads settled to the bottom of the tube. The beads were washed twice with PB to clear the 
beads of elution buffer and detached IgG molecules. 
 To further solubilize the partially insoluble VJ WT outer membrane sample in this 
experiment, 240 µL of 0.1 M PB with 0.2% Triton X-100 (Mallinckrodt) was added to 
160 µL of VJ WT outer membrane sample. The sample volume used for this experiment 
was determined from previous Western blots that used the original OD600 of the VJ WT 
outer membrane stock (which was 47.7 from 20 plates). The sample mix was incubated at 
room temperature with gentle shaking for 30 min. The solution was ultracentrifuged at 
100,000 g for 1 hour at 4°C and the supernatant was removed and diluted by half with 
0.1M PB to a concentration of 0.1% Triton X-100. The leftover pellet was resuspended in 
0.1M PB with 1.0% Triton X-100 and ultracentrifuged as before, and the supernatant was 
diluted to a concentration of 0.1% Triton X-100. The pellet was kept and labelled “OM 
unlysed”. 
 The lysed outer membrane mixture and the prepared anti-HopE protein G beads 
were incubated overnight at 4°C with gentle agitation. To perform the pulldown, the 
resulting protein and bead mix were transferred to a Nanosep 3K omega centricon tube 
(Pall Corporation). This tube was used as separating the beads from the surrounding 
solution proved difficult in the previous steps of this experiment, resulting in a minor loss 
of beads each time supernatant was removed. It was expected that using a centricon tube 
would prevent loss of beads as the solution could pass through the membrane unimpeded 
and separate from the beads.  
 After the overnight incubation, the beads were then centrifuged as according to 
centricon manufacturer instruction, at 13,000 g at 4oC for 15 minutes for the supernatant 
to be removed. The supernatant was labelled “Unbound”. The beads were washed three 
more times in 0.1 M PB containing 0.1% Triton X (to prevent aggregation and maintain 
protein solubilization). Before the elution step, the beads were changed to a Nanosep 30K 
omega centricon tube to allow the HopE protein to pass through the membrane and into 
the filtrate receiver. To elute the HopE protein from the antibody complex, 100 µL of 0.1 
M glycine HCl (pH 2.5) was added to the beads and the tube was centrifuged at 5,000 g 
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for 5 min at 4oC. The supernatant was recovered (“Elution”) and the acidity quenched 
with an equivalent amount of 1N NaOH and checked with pH strips to ensure a neutral 
pH. The elutions were analyzed on a Western blot. 
 
2.12 Statistical analysis  
Raw data was input into Graphpad Prism 6 software and all calculations including means 
and standard errors and statistical analyses were performed using this software. 
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3 Results 
3.1 Optimization of the detection of HopE using anti-HopE 
antibodies 
Rationale: 
Previously, using biotin-hydrazide labeling, anti-Lewis Western blotting, and 
silver staining of outer membranes, our lab discovered that H. pylori (HP) strain NCTC 
11637 contained a ~31 kDa Lewis Y glycoprotein. Mass spectrometry and enrichment by 
lectin affinity chromatography potentially identified this protein as the HopE porin that 
may be glycosylated by a Lewis Y antigen. To confirm this, a hopE knockout mutant was 
constructed; anti-Lewis Y Western blotting of the outer membranes determined that this 
~31 kDa protein was present in the wild-type but absent in the knockout mutant. The MS 
data also identified a putative glycopeptide that partially matched the amino acid 
sequence of HopE which had 3 potential glycosylation sites: O-glycosylation on a serine 
or threonine, and a N-glycosylation consensus sequence reading as Asn-Ala-Thr. 
Modelling by Dr. Creuzenet (Figure 5) indicated that this putative glycopeptide was 
likely localized on the surface of the outer membrane, implicating its possible role in host 
mimicry, immune evasion, or adhesion to host tissues.  
However, at that time there were no antibodies to detect the HopE and verify if it 
was HopE that was reacting to the anti-Lewis Y antibodies. To overcome this problem, 
Dr. Creuzenet ordered rabbit antibodies (from ProSci Inc.) against a portion of HopE, 
specifically a 15-amino acid sequence relating to a surface-exposed peptide loop: 
GYKKFFQFKSLDMTS. This section of HopE was chosen for a several reasons. Firstly, 
we needed the epitope to be from a portion of HopE that faced the outside of the cell, in 
order to use this antibody for detecting the protein when subjected to whole cells. This 
would be useful, for example, if the antibody is to be used to probe for interactions 
between the HP and gastric cells. Secondly, the epitope also needed to be on an area that 
was not near the location of the glycan, to prevent masking of that location if the Western 
blot was re-probed with anti-Lewis Y. Lastly, this epitope was one of the few acceptable 
locations that was found to be immunogenic according to in silico analysis.  
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Results: 
Two rabbits were immunized against this amino acid sequence (rabbit #1 and #2). 
The ELISA titer results, obtained from the serum supplier, for the final bleed showed that 
rabbit #1 had a lower ELISA titer than rabbit #2. Thus, we began working to optimize the 
antibody detection of HopE on Western blot using the serum from rabbit #2 (Figure 6).  
 
 
Figure 6. Timeline of polyclonal antibody production and ELISA results for both 
rabbits.  
Two pathogen-specific free rabbits were immunized with the HopE epitope multiple 
times over a period of months. The ELISA titer results were quantified by ProSci and 
compared the pre-bleed versus the final bleed for both rabbit sera. The red circle in the 
ELISA table points out the larger antibody titer in rabbit #2.  
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As we did not know which bleed would give us the best detection of the HopE 
protein without much background signal, and at which dilution, we tested all bleeds at 
various dilutions, ranging from 1/200 to 1/1000. The pre-immune serum was used as a 
comparison against the three bleeds; it was not exposed to the HopE peptide so the 
antibodies from the pre-immune serum should not react to HopE. We also only used 
outer membrane (OM) samples (separated from the rest of the bacterial components using 
ultracentrifugation and differential solubilization with N-laurylsarcosine), as we knew 
HopE was an outer membrane porin, in order to minimize background signals and enrich 
the protein of interest. To better resolve proteins of lower molecular weight (MW), we 
created a stepwise gel and ran the OM samples of WT and the hopE knockout mutant 
(Figure 7). 
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Figure 7. Optimizing the anti-HopE antibodies for Western blotting.  
The bacterial cells were lysed by mechanical disruption and the OM components were 
separated via ultracentrifugation. Western blotting was performed on OM samples using 
anti-HopE antibodies. The red horizontal lines mean the demarcation of transition from 
20-16% and 16-12% acrylamide (the gel layout is shown at the top right). Left pink blots 
are due to Ponceaus S red staining of proteins. The nitrocellulose membrane was cut into 
strips and incubated separately according to the serum bleed and concentration. Red box 
= protein band ~27 kDa that is non-reactive to pre-immune in WT and both pre-immune 
and all bleeds in the hopE knockout mutant. The bottom right image depicts the current 
final application of the anti-HopE Western blotting; red arrow denotes the location of the 
HopE band. M = molecular weight marker. 
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The red box in Figure 7 denotes a protein band smaller than 30 kDa that is not 
reactive in the pre-immune stage but reactive in the bleeds in WT. This protein is also not 
present in the hopE mutant blot. The bleed that was chosen to perform further anti-HopE 
Western blotting was from the final bleed (bleed 4) at a concentration of 1/200. Based on 
these experiments, HopE could be reliably detected using the optimized anti-HopE 
Western blot conditions. 
A vast number of protein bands were also reactive to these new HopE antibodies. 
Thus, we investigated the reason behind this by comparing the peptide sequence used to 
raise the antibodies against the OM proteins (OMPs) of HP. To date, we have compiled a 
list (Figure 8) of OMP sequences that was obtained by blasting HopE against the HP 
genome using the NCBI protein BLAST online tool. The results indicated that our 
peptide sequence that we used for rabbit immunization (GYKKFFQFKSLDMTS) is 
found in many OMPs, although with varying levels of conservation. However, this may 
not be the cause of the cross-reactivity, as the naïve pre-immunized serum also has this 
similar pattern of cross-reactivity (Figure 7). Nevertheless, the cause of this phenomenon 
was not pursed further because these bands do not prevent us from detecting our protein 
of interest. 
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Figure 8. Complete list of OMPs that have similarities to the HopE epitope. 
The green highlighted box indicates the location within the 28 non-HopE outer 
membrane protein sequences that have a high degree of consensus with the HopE 
epitope. The red amino acids are found within all the genes at that location, while the 
blue amino acids are found within the majority of the genes at that location. 
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  All strains generated for this study 
3.2.1 Initial strains available in the lab and problems encountered 
 Some of the original strains that had been ready for preliminary investigation 
were a WT and a ΔhopE mutant derived from this WT, labelled Maryam Khodai (MK) 
WT and Brandon Oickle (BO) ΔhopE mutant, respectively. Due to the repeated passages 
of MK WT separate from its ΔhopE mutant, we could not be certain that the pair 
remained isogenic. It was possible that because the WT was carried independently, phase 
variation might have occurred, which concerns the LPS synthesis fucosyltransferase 
genes. In order to standardize the Western blot and antibiotic testing results, the LPS 
patterns of all the strains must be taken into account as they matter greatly when 
interpreting the results of antibiotic sensitivity assays presented later, since the LPS can 
play a role as a barrier to prevent intake of the antibiotic. Additionally, the LPS can also 
cause interference in identifying Lewis Y or BambL reactive proteins and diminish the 
observation of phenotypes that relate to proteins on the surface of the cell. Therefore, 
finding or creating closely matching strains in terms of LPS patterns is important to 
isolate phenotypes specifically due to HopE. 
 
3.2.2 Generation of mutants relevant to this study 
Rationale for VJ ΔhopE: 
Since the MK WT had been passaged repeatedly by other lab members and may 
suffer from phase variation that alters surface properties, the VJ ΔhopE was generated 
during this thesis work using VJ WT as the recipient (Figure 9), therefore producing an 
isogenic pair. 
Results for VJ ΔhopE: 
Transformation of the hopE knockout construct into the VJ WT strain resulted in 
the production of 4 clones (Figure 9). Screening these clones via PCR and DNA 
sequencing indicated that several clones had successfully incorporated the 
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chloramphenicol resistance (CAT) cassette into the hopE gene, producing VJ ΔhopE. 
Clone #2 was chosen to be the isogenic pair to VJ WT and its outer membrane was 
extracted for subsequent analysis. 
 
 
Figure 9. Creation of VJ ΔhopE. 
The location of primers used for the analysis is shown in the schematic next to the gel 
results. Succesful insertion of the hopE knockout construct was verified by the presence 
of the hopE chloramphenical (CAT) resistance cassette (size of this PCR product would 
be 1618 bp). Wild-type control without the cassette in hopE (- CAT) had a PCR product 
size of 1463 bp. L = molecular weight standards. 
 
Rationale for ΔhopE/ΔwaaL: 
To better visualize the HopE protein and its potential Lewis glycosylation in 
absence of LPS, we created the double knockout mutant ΔhopE/ΔwaaL by inserting the 
hopE knockout construct into the ΔwaaL strain through natural transformation (Figure 
10). With the O-antigen ligase function knocked out, there would be no fully formed LPS 
structure although O-units of Lewis Y antigens would still be formed. Thus, it should 
have no LPS-based Lewis Y reactivity while any glycoprotein-based reactivity would be 
present during Western blotting. Additionally, this double knockout mutant would also 
provide information on the function of HopE during assays to investigate its role, as 
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removal of the LPS may provide greater access to the porin on the outer membrane. This 
double knockout mutant would be compared to the reference strains ΔwaaL and ΔhopE 
and is isogenic to ΔwaaL. 
One caveat to mention is that if WaaL is responsible for HopE glycosylation by 
transferring the Lewis Y onto HopE, then this double knockout mutant would not show 
any difference of Lewis Y reactivity when compared to the single ΔwaaL mutant. 
However, according to our hypothesis, the OST is not WaaL but is HP0946. We still 
carried out systematic studies using the WT WaaL strains to ascertain if WaaL was 
involved (Figure 10). 
Results for ΔhopE/ΔwaaL: 
Performing the transformation of ΔhopE/ΔwaaL resulted in the generation of 20 
clones (Figure 10). The first ten were screened by PCR and their chromosomal DNA was 
extracted. The resulting screening and DNA sequencing indicated that several clones had 
successfully incorporated the chloramphenicol resistance (CAT) cassette into the hopE 
gene and of these, clone #10 was selected for downstream applications. As such, we 
proceeded to extract the outer membranes of this double knockout mutant clone. 
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Figure 10. Generation of ΔwaaL/ΔhopE and the resulting PCR analysis. 
The location of primers used for the analysis is shown in the schematic above the 
corresponding DNA gels. A) The presence of the hopE chloramphenical (CAT) 
resistance cassette increased size of the PCR product to 1618 bp. Lack of the cassette 
resulted in a product of 1463 bp. B) Clones with the kanamycin (Kan) resistance cassette 
in the correct location had a product size of 2958 bp. Strains without the kanamycin 
cassette in waaL had a PCR product size of 2103 bp. L = molecular weight standards. 
 
Rationale for ΔhopE/Δ946: 
According to anti-Lewis Y and BambL Western blots (shown later, Figures 14 
and 17), the LPS patterns of the WTs did not correspond well to the LPS patterns of the 
ΔhopE mutants or the Δ946 mutant. This renders an accurate comparison between the 
WT and the mutants difficult, as several of the assays performed in my project may be 
affected by the composition/arrangement of the LPS pattern. However, the ΔhopE 
mutants and the Δ946 mutant have similar LPS patterns (they have more abundant lower 
molecular weight LPS molecules than the WTs in the anti-Lewis Y blots), thus it would 
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be desirable to make a double knockout mutant using the Δ946 strain as the backbone in 
which to incorporate the ΔhopE construct. In this manner, the double knockout mutant 
can be compared to its respective single knockout mutants, using them as the reference 
instead of the WTs which do not have a matching LPS pattern. Unlike the ΔhopE/ΔwaaL 
double knockout mutant which does not have functional LPS pattern, this double 
knockout mutant will still have LPS O-antigen and is isogenic to Δ946 (Figure 11).  
Results for ΔhopE/Δ946: 
After the transformation of ΔhopE/Δ946, 9 clones were obtained and their 
chromosomal DNA was extracted and screened by PCR. All the tested clones showed a 
PCR band consistent with the expected size. However, since the difference between the 
clones and the controls without the CAT cassette are minimal and could not be resolved 
on the agarose gel, DNA sequencing was performed. DNA sequencing indicated that 
several clones had successfully incorporated the chloramphenicol resistance (CAT) 
cassette into the hopE gene (Figure 11) and of these, clone #6 and #7 were selected for 
antibiotic assays. Additionally, the outer membrane was extracted from this double 
knockout mutant clone #7 and Western blots and silver staining (with Proteinase K 
treatment) was performed.  
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Figure 11. Creation of the ΔhopE/Δ946 double knockout mutant and the resulting 
PCR analysis. 
The location of all primers is shown in the schematic above the gel result. Presence of the 
hopE chloramphenical (CAT) resistance cassette in hopE is indicated by the PCR product 
size of 1618 bp. Absence of the CAT cassette in hopE is indicated by the product size of 
1463 bp. The ΔhopE construct was transformed into the Δ946 mutant that had been 
previously verified by another lab mate, Justine Denomme. L = molecular weight 
standards. 
 
3.2.3 PCR analysis of the LPS synthesis-related genes for phase 
variation 
Rationale: 
In addition to ensuring that the various strains had the proper sequence in the 
genes of interest, the fucosyltransferases FutA and FutC and the Wzk flippase genes 
underwent PCR and sequencing analysis. The fucosyltransferases are enzymes required 
for the production of Lewis antigens, as well as LPS chain length regulation and have 
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highly phase variable regions in their genes31. The Wzk enzyme, while not phase 
variable, is the flippase that transfers the O polysaccharide unit to the periplasm, where 
the WaaL O antigen ligase attaches it to the lipid A core23. Thus, changes to these genes 
could significantly affect the LPS structure of the bacteria, possibly resulting in 
phenotypic changes such as a change in antibiotic susceptibility. However, the 
fucosyltransferases are not the only genes with homopolymeric tracts that may potentially 
inactivate their function. In fact, there are a total of 27 phase variable genes in all of HP72.  
Results: 
 Analysis of the FutA, FutC and Wzk genes show no difference between the FutA 
and Wzk sequences of all the strains; the enzymes were all in frame and therefore should 
be functioning properly. The FutC gene was not in frame for most of the strains, 
indicating that the full protein is likely not formed. However, it is likely that a truncated 
form of FutC is still functioning, since the strains capable of making O-antigens are still 
producing bands that react to Lewis Y (seen in anti-Lewis Y Western blotting). As FutC 
is the only known enzyme in the LPS synthesis pathway that can create the Lewis Y 
motif (see Figure 4), it is possible that since frame shifting occurs after the motif I, this 
may be enough to perform the catalytic function of attaching the terminal fucose.   
 
3.2.4 Analysis of the LPS of working H. pylori strains 
Rationale: 
In order to determine the LPS pattern of the various strains, samples were treated 
with Proteinase K (PK) and subjected to silver staining. This procedure should eliminate 
protein signals and allow the observation of each strain’s LPS profile. Additionally, it 
could identify potential LPS present in the silver stain that is neither Lewis Y nor BambL 
reactive. Sample loading was reduced as silver staining is a highly sensitive method that 
does not require the same volume of sample input as the Western blots do.  
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Although the OM preparations were made from normalized samples of the HP 
strains (same optical density during harvest, same volumes used during OM extraction), 
the volume of sample to use for these gels were refined using the Ponceau S stains of 
Western blots to ensure that all the samples were loaded equally according to protein 
content. Concurrently, a Coomassie stain to detect proteins was also performed with the 
same samples to identify any proteins that may not have degraded completely during the 
PK treatment and might be mistaken for LPS in the silver stain. Additionally, to identify 
LPS patterns using anti-Lewis Y and BambL, the OM samples were digested with 
Proteinase K and their LPS was detected via Western blotting. 
Results: 
The silver staining results (Figure 12A) showed that the ΔhopE and Δ946 mutants 
had higher molecular weight silver-reactive bands (~31 – 40 kDa, indicated by a green 
bracket), that are either undigested proteins or LPS. According to the Coomassie stain, 
these bands are not proteins that were resistant to digestion as there is no Coomassie 
reactivity in that area, thus they are likely LPS molecules. However, this silver response 
was not seen in the WTs and ΔwaaL and ΔhopE/ΔwaaL double knockout mutant. As the 
ΔwaaL and ΔhopE/ΔwaaL mutants do not have a functional O-antigen ligase, the lack of 
this LPS is understandable. This is not as easily explained in the WT strains; the two WT 
strains also had less lipid-A core than the other mutants. Thus, it is possible that despite 
our best efforts at calculating to aim for equal loading, WT samples were loaded less than 
the other strains. To determine if this was the case, silver staining was performed again 
on new samples. 
According to Figure 12B, the O-antigen products of the newly prepared OM 
sample of the VJ WT strain was clearly visible unlike in Figure 12A. This indicated that 
despite obtaining OM samples for all strains at similar optical densities with no changes 
in the extracting of the OM component, there was still variations in the silver stain 
response. It appears that OM samples weren’t precisely reproducible due to the likelihood 
of variable O-antigen expression. The variation of HP’s O-antigen expression could also 
affect antibiotic assays as the LPS plays a crucial role in repelling antibiotics. Thus, it 
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was essential to perform 3 independent biological replicates for all antibiotics assays 
conducted in this thesis. Figure 12B also provides a comparison of the newly extracted 
ΔhopE/Δ946 double knockout mutant with its isogenic Δ946 mutant. No difference in 
this LPS pattern was seen, as expected and antibiotic assays can be performed and 
compared between these two strains and ΔhopE faithfully. Overall, ΔhopE does not 
change the LPS pattern when comparisons are made with the properly matched isogenic 
strains. 
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Figure 12. Silver and Coomassie staining of Proteinase K treated samples. 
OM samples were subjected to Proteinase K (PK) treatment and subsequently run on 
BioRad precast gradient gels, 4-20%. A) One gel was developed with silver (left) and the 
other with Coomassie (right). B) After staining the lipid-A core, the gel was cut along the 
red dashed lines and re-stained with silver to expose the higher molecular weight bands. 
Location of the LPS O-antigen is seen with the green bracket. Red star indicates location 
of the lipid-A core. M = molecular weight markers. 
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Results of the anti-Lewis Y and BambL blots showed the different LPS pattern 
between the two WTs, making it clear that MK WT’s LPS profile appears to have been 
altered in some way. This does not mirror the results of the silver stain, causing a 
paradox. Silver staining is reportedly very sensitive, which is why less OM samples are to 
be used when staining them with silver since they react so strongly. However, it is very 
evident when comparing Figures 12 and 13 that the silver stain could not pick up the 
higher molecular weight bands (greater than 40 kDa) seen using anti-Lewis Y antibodies 
and BambL lectin. The reason for this was not investigated further at this point, 
especially since MK WT had proved not to be isogenic to the BO ΔhopE mutant.  
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Figure 13. Visualizing the LPS pattern via anti-Lewis Y and BambL Western 
blotting of PK treated OM samples. 
OM samples were subjected to Proteinase K (PK) treatment and subsequently run on 
BioRad precast gradient gels, 4-20%. The membranes were cut in half, one-half 
incubated for anti-Lewis Y blotting and the other half for BambL blotting. Membranes 
were also stained with Ponceau to visualize any undigested proteins. M = molecular 
weight markers. 
  
3.2.5 Analyzed characteristics of the working H. pylori strains 
 During the course of this thesis, the relevant characteristics of the working strains 
were consolidated into a table (Table 3). The working strains used were VJ WT, MK WT, 
VJ ΔhopE, BO ΔhopE, Δ946, ΔwaaL, ΔhopE/ΔwaaL, and ΔhopE/Δ946. As the table 
illustrates, there appears to be no difference in the silver stain LPS pattern for isogenic 
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strains with a functional waaL gene. However, there does appear to be differences in the 
LPS pattern when visualized using PK treated samples in anti-Lewis Y and BambL blots 
(Figure 13). To understand the reasoning behind this phenomenon, the 
fucosyltransferases FutA and FutC and the Wzk flippase were analyzed via PCR. 
Sequence analysis of the fucosyltransferase PCR products indicated that there were no 
differences between the gene sequences of these strains that could explain the LPS 
variation. Likely, this LPS variation is a consequence of other genes such as the 
remaining 25 phase variable genes. It does appear that most genes do not have an “in-
frame” FutC gene. However, since the strains are reacting to the Lewis Y antibodies, it is 
likely that the FutC gene is still functional by virtue of its most N-terminal transferase 
domain that is in frame. Although ΔhopE/ΔwaaL’s FutC is in-frame, the deletion of the 
waaL gene prevents LPS from being incorporated onto the outer membrane, thus it is not 
relevant that FutC’s sequence in ΔhopE/ΔwaaL is different from the other strains since 
the LPS result of FutC being in frame would not be observed. However, it is relevant in 
terms of the nature of the O-antigen units that can be made and are available for 
glycosylation.  
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Table 3. List of features that have been analyzed for all working strains. 
 
“Gene is not in frame” signifies that the strain is missing a 15th C base in the homopolyC 
tract of FutC that would render the gene “in-frame”.  
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 Investigating HopE glycosylation with anti-Lewis Y 
Rationale:  
To determine the possibility of HopE glycosylation, the OM samples of several of 
the strains were extracted and run on commercially produced precast 4-20% gradient 
gels. These gels are the same as those used for LPS analyses described above in section 
3.2 and were utilized to replace the home-made step-wise gels shown in Figure 7 in an 
attempt to obtain more reproducible Western blots and defined protein/LPS bands to 
allow for easier comparison between samples in a single blot and between two or more 
different blots. Additionally, the use of these gradient gels may also allow easier 
resolution of the HopE band away from the Lewis Y reactive LPS bands. When 
performing this Western blot, half of the membrane was blotted with anti-HopE 
antibodies while the other half was blotted with anti-Lewis Y antibodies. 
Results:  
In Figure 14A, comparing the lanes with strains containing HopE indicated by the 
red arrows (VJ WT, MK WT, Δ946, ΔwaaL) to those with the hopE gene knocked out, 
anti-Lewis Y signal intensity does not change (bottom panel) or even increases (top 
panel). If HopE was truly glycosylated by a Lewis motif, the elimination of HopE should 
result in a notable decrease in anti-Lewis Y signal in the ΔhopE mutants. This indicates 
that HopE may not be glycosylated with Lewis Y. Additionally, the Lewis Y signal is 
still present in the ΔhopE/ΔwaaL mutant in the HopE region, further indicating that 
HopE is not glycosylated by Lewis Y. However, presence of Lewis Y reactive bands in 
the ΔhopE/ΔwaaL and ΔwaaL mutants suggest the possible presence of other Lewis Y 
glycosylated proteins, since the LPS O-antigen is eliminated from these two mutants. 
In Figure 14B, the Western blots in Figure 14A were manipulated in Photoshop 
by inverting the colours that appear when scanning the membrane (red wavelength 
became blue, green wavelength became pink) to provide better visualization when these 
blots were overlayed on top of each other. This analysis was performed to provide more 
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proof of the possible lack of Lewis Y HopE glycosylation. If an anti-HopE reactive band 
was also reacting to anti-Lewis Y, the band would show as purple.  
However, these overlays did not work as well as they could have, due to 
differences of migration of the samples in the lanes for the anti-HopE blot versus the 
lanes for the anti-Lewis Y blot in the left panel. The VJ WT and the ΔwaaL lanes 
experienced a slight lane distortion upward in the anti-Lewis Y blot but downward in the 
anti-HopE blot, making it impossible to overlay the bands. In this blot, we can only 
accurately compare the overlays of the middle two lanes (VJ ΔhopE and Δ946) as the 
samples did not distort in either the anti-HopE or anti-Lewis Y blots. Therefore, the 
HopE band in Δ946 coincides with a Lewis Y band, but that band is still present in the VJ 
ΔhopE mutant, thus it is likely that the Lewis Y signal is not due to HopE glycosylation. 
For the right-side panel, very little distortion was observed, making overlaying the two 
blots possible. As there is still a blue Lewis Y reactive band in this ΔhopE mutant, these 
inverted blots have the potential to provide further evidence that the Lewis Y reactive 
band is not HopE. 
Interestingly in the anti-Lewis Y Western blot, the Δ946 mutant exhibits a Lewis 
Y pattern that is entirely different than the other strains. As the function of HP0946 is 
unknown, complementation of this protein could confirm whether this altered Lewis Y 
pattern is a product of eliminating HP0946. However, this was not attempted yet due to 
time constraints. 
To determine the specificity of the anti-HopE and anti-Lewis Y Western blot 
results, blotting half the membranes with only secondary antibodies (Figure 15 and 16, “- 
primary”) showed that the secondary goat anti-rabbit antibodies (that bind to anti-HopE 
antibodies) and the secondary goat anti-mouse antibodies (that bind to anti-Lewis Y 
antibodies) elicited very little cross-reactivity. The results of Figure 15 implied that there 
is low non-specific binding by the secondary antibody. Similarly, the results of Figure 16 
also indicated that the anti-Lewis Y Western blotting membranes blotted with both 
antibodies were very specific and is likely only reacting with bands that contain Lewis Y 
antigens. 
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Figure 14. Ponceau S stain and Western blot to investigate HopE glycosylation by 
Lewis Y. 
A) Western blot of OM preparations detected with anti-HopE and anti-Lewis Y 
antibodies on precast gradient gels (4-20%). Ponceau S stained membranes are shown on 
the left to visualize proteins. The red dashed lines indicate that the ΔhopE and 
ΔhopE/Δ946 mutants shown together were run on different gels at a later date to the rest 
of the blot. Alignments were performed based on the molecular weight marker locations 
and overlaying blots and matching the markers on both blots to each other. Sometimes, 
non-specifically reacting protein bands on both blots are also aligned. Alignment via this 
method is not always absolute as there are two separate membranes being used in which 
warping can occur. B) Enhanced view of the two blots. The blots were inverted to obtain 
the pink and blue colours using Photoshop in order to better visualize the bands when 
they are overlayed on top of each other. The red arrow indicates the location of the HopE 
band. M = molecular weight markers. 
 
 
  
57 
 
 
Figure 15. Ponceau S staining and anti-HopE Western blot of OM samples to 
determine antibody specificity. 
Western blot of OM samples on gradient gels (4-20%), detected with freshly made anti-
HopE primary and secondary antibodies. Ponceau S stained membranes are shown on the 
right to visualize proteins. M = molecular weight markers. 
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Figure 16. Ponceau S staining and anti-Lewis Y Western blotting of OM samples to 
determine antibody specificity. 
Western blot of OM samples on gradient gels (4-20%), detected with freshly made anti-
Lewis Y primary and secondary antibodies. Ponceau S stained membranes are shown on 
the left to visualize proteins. M = molecular weight markers. 
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 Investigating HopE glycosylation with lectin BambL 
Rationale:  
Although HopE is likely not glycosylated by Lewis Y, this does not eliminate the 
possibility that HopE is glycosylated with a non-Lewis Y glycan. To investigate this 
possibility, a Western blot was performed with fucose binding biotinylated lectin BambL 
and fluorescently labelled streptavidin. After blotting half of the membrane with this 
BambL the blot was re-probed with anti-HopE antibodies to determine the location of 
HopE; this strategy allows direct overlay of both blots. The original blots and enhanced 
blots are shown in Figure 17.  
Results: 
Comparing the isogenic strains containing HopE in Figure 17 to the strains 
without it (HopE is indicated by the red arrows), the BambL reactive band appears to be 
lost when the porin expression is eliminated in the hopE knockout mutants. This is 
particularly apparent on the blot overlays. Thus, HopE may be glycosylated by another 
fucose carrying glycan.  
Interestingly, removal of the HopE protein results in increased generation of 
higher molecular weight fucose-containing bands (that are reactive with BambL) not seen 
in the WT strains (indicated by the yellow brackets). The generation of higher molecular 
weight BambL reactive bands is enhanced even more when eliminating the HP0946 
protein, whose function is still unknown. Indeed, this phenotype is also seen in the double 
knockout mutant ΔhopE/Δ946. It is likely that within the Δ946 mutant, the higher 
molecular weight bands are Lewis Y O-antigens, as this BambL pattern is present in the 
Lewis Y Western blots as well. Additionally, there is still BambL reactivity within the 
HopE area for the Δ946 mutant, which is confirmed when comparing to the WT, ΔhopE 
mutant and ΔhopE/Δ946 mutant.  providing evidence that HP0946 may not be the OST 
for HopE glycosylation. BambL reactivity also appears to be conserved in the ΔwaaL 
mutant, therefore WaaL would also not be responsible for HopE glycosylation by the 
BambL reactive motif. 
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 According to Figure 18, observing the BambL + streptavidin blots against the 
streptavidin only blots shows there is very little non-specific binding occurring due to 
incubation with streptavidin. 
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Figure 17. Ponceau S staining and Western blotting with BambL to investigate 
HopE glycosylation. 
A) Western blot of OM preparations detected with BambL and anti-HopE antibodies on 
BioRad precast gradient gels (4-20%). Anti-HopE antibodies were used to re-probe the 
same membrane that had been incubated with BambL. Ponceau S stained membranes are 
shown on the left to visualize proteins. The red dashed lines indicate that the ΔhopE and 
ΔhopE/Δ946 mutants shown together were run on different gels at a later date to the rest 
of the blot. Alignments were performed based on the molecular weight marker locations 
and overlaying blots. Sometimes, non-specifically reacting protein bands on both blots 
are also aligned. B) Enhanced view of the two blots. The blots were inverted to obtain the 
pink and blue colours using Photoshop in order to better visualize the bands when they 
are overlayed on top of each other. The red arrow indicates the location of the HopE 
band. The legend at the bottom matches the colour of each outlined box to its respective 
antibody/lectin. M = molecular weight markers. 
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Figure 18. Ponceau S staining and Western blotting to detect non-specific binding 
by BambL lectin. 
Western blot of OM samples with BambL and streptavidin on gradient gels (4-20%). 
Ponceau S stained membranes are shown on the left to visualize proteins. The “No 
BambL” portion of the membranes were generated to visualize non-specific binding of 
fluorescently labelled streptavidin. M = molecular weight markers.   
64 
 
 Immunoprecipitation of HopE to obtain target protein 
Rationale:  
To reduce non-specific binding of antibodies to non-HopE proteins and LPS and 
to gain further evidence for/against the putative glycosylation of HopE, we aimed to 
isolate the HopE protein and perform targeted Western blotting (anti-Lewis Y and anti-
HopE) without any interfering proteins or LPS. BambL Western blotting was also 
performed to determine the possibility of HopE being glycosylated by another 
fucosylated glycan. 
Results: 
Initially, the OM of VJ WT was lysed twice with the detergent Triton X-100; the 
first time with 0.2% Triton X-100 and the second time with 1% Triton X-100. The first 
lysate was then diluted by half to achieve an overall concentration of 0.1% Triton X-100 
while the second lysate was diluted ten-fold before a sample was taken for gel analysis. 
These dilutions were performed to ensure that the concentration of the detergent did not 
affect downstream applications such as binding the lysate sample to the protein G-
antibody mix.  
The first lysate was incubated with the protein G-antibody mix because the 
concentration of HopE within the first lysate was more concentrated. As it was unclear 
how well the lysing with Triton X-100 would be in releasing HopE, the leftover insoluble 
unlysed portion of the OM preparations was also kept and run on the 12% SDS PAGE 
gel. The anti-HopE blot in Figure 19 shows that because HopE did not bind well to the 
protein G-antibody linked beads, it eluted in the unbound and wash steps. The protein 
that did elute in the elution step was roughly 50-55 kDa and is likely the heavy chain of 
the IgG antibody. However, it did appear that there were less non-HopE proteins being 
pulled down during this assay. There was not as many proteins reacting non-specifically 
to anti-HopE antibodies and less non-HopE reactivity in the Ponceau S stain as compared 
to the control lanes with OM samples of VJ WT and VJ ΔhopE. Thus, the blots are 
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cleaner than the other Western blots done without this process and our goal for 
performing this experiment was a success. 
After blotting with the anti-HopE antibody, to determine the possibility of Lewis 
Y glycosylation, the membrane was re-probed with anti-Lewis Y (Figure 19). As the anti-
Lewis Y blot indicates, there is no reactivity to the HopE band. This provides further 
confirmation that HopE is not glycosylated with Lewis Y. 
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Figure 19. Immunoprecipitation of HopE results with Ponceau S, anti-HopE, and 
anti-Lewis Y detection. 
After the immunoprecipitation attempt to elute HopE protein, all fractions of the 
immunoprecipitation assay were run on 12% SDS PAGE gels. Proceeding the Ponceau S 
staining and probing with anti-HopE, the same membrane was then re-probed with anti-
Lewis Y. The red arrow indicates the location of HopE. Under the larger blots, the area of 
interest has been enhanced for easier visualization. M = molecular weight markers.  
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BambL Western blotting was also performed and compared to the anti-Lewis Y 
and anti-HopE blots (Figure 20). When the BambL and anti-HopE blots are examined 
together, the HopE band appears to be reacting to BambL. This is quite evident when 
viewing the OM control lanes for VJ WT and VJ ΔhopE; the HopE band clearly reacts to 
BambL in the WT while the lack of HopE expression in VJ ΔhopE also results in the lack 
of BambL reactivity in that area. This is significant considering that both samples were 
loaded equally according to the Ponceau S stain. When comparing this to the unbound 
and wash lanes, the BambL reactivity of HopE, although fainter than in the VJ WT 
control, is visible. This provides further evidence to the idea that HopE is glycosylated by 
a non-Lewis Y glycan that is fucosylated. Thus, glycosylation of HopE could still be 
linked to the LPS pathway via the fucosyltransferases that would be involved in 
generating this fucosylated glycan. 
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Figure 20. Immunoprecipitation of HopE results with Ponceau S, anti-HopE, and 
BambL detection. 
After the immunoprecipitation attempt to elute HopE protein, all fractions of the 
immunoprecipitation assay were run on 12% SDS PAGE gels. Proceeding the Ponceau S 
staining and probing with BambL, the same membrane was then re-probed with anti-
HopE. The red arrow indicates the location of HopE. Under the larger blots, the area of 
interest has been enhanced for easier visualization. M = molecular weight markers. 
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 Testing HopE’s role in antibiotic susceptibility/resistance 
via antibiotic sensitivity assays 
Rationale:  
Etest strips and disk diffusion methods were utilized to discover significant 
phenotypes amongst the ΔhopE mutants when compared to the WTs, ΔwaaL (in the case 
of ΔhopE/ΔwaaL) or Δ946 (in the case of ΔhopE/Δ946). Performing both assays would 
help solidify any phenotypic variations we see between strains, as the results should be 
complementary to each other. 
Results: 
Table 4 shows the three different antibiotics that were used in this thesis. All three 
antibiotics are of different classes, have differing sizes and function via different 
mechanisms of action. This allowed us to observe the effect of HopE when subjected to 
antibiotics with varying attributes.  
The levofloxacin Etest results demonstrate that VJ ΔhopE performs similarly to 
the WTs; removal of HopE sustains the same phenotype as VJ WT. Additionally, 
removal of HopE in the ΔwaaL mutant maintains the ΔwaaL phenotype in the 
ΔhopE/ΔwaaL mutant and removing HopE in the ΔhopE/Δ946 mutant keeps the Δ946 
phenotype (Table 5). Therefore, eliminating the porin HopE does not affect the minimum 
inhibitory concentration (MIC) compared with the original strains indicating that HopE 
does not play a role in levofloxacin susceptibility.  
When observing the results in the amoxicillin Etest, all strains have the same MIC 
values except ΔwaaL and ΔhopE/ΔwaaL, with these two having the same lower MIC 
(Table 5). Thus, HopE does not influence the susceptibility of H. pylori to amoxicillin, 
similarly to the levofloxacin results. Overall, there is no significant difference between 
the strains, as CLSI standards dictate that significance is noted only if MICs are 4-fold 
dilutions apart. 
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The ΔhopE mutants within the disk diffusion assay (Figure 21) did not elicit a 
significant difference compared to the WTs, or the other background strains (ΔwaaL and 
Δ946) in which the ΔhopE/ΔwaaL and ΔhopE/Δ946 mutants were made. This further 
indicates that the HopE porin likely does not play a role in antibiotic susceptibility. 
However, knocking out the HP0946 protein did result in greater susceptibility to 
clarithromycin in the disk diffusion assay, in a similar level of susceptibility as the 
ΔwaaL and the ΔhopE/ΔwaaL mutants.  
With the loss of the full LPS barrier (specifically the O-antigen) against 
antibiotics for the mutants ΔwaaL and ΔhopE/ΔwaaL, this explains their increased 
susceptibility to antibiotics. However, this explanation can not be applied to Δ946, as the 
strain still produces what appears to be the full LPS O-antigen as evidenced by the anti-
Lewis Y and BambL blots. An alternative explanation is yet to be discovered. It would be 
interesting to learn more about this protein in the future.  
 
Table 4. Characteristics of antibiotics used for assessing antibiotic sensitivity. 
 
The antibiotics used within this thesis are separated into several features. They all vary 
significantly in most characteristics. 
71 
 
Table 5. Results of the levofloxacin and amoxicillin Etest. 
 
This Etest strip test was conducted on three different days with H. pylori strains grown 
separately (N = 3). Cells were plated at a density of OD600 = 0.5. The brackets indicate 
strains that are apparently isogenic and can be compared. The MIC values that are in a 
range indicate that the strain varied in their response to the antibiotic once in the three 
replicates that were performed. 
 
Figure 21. Results of the clarithromycin disk diffusion assay. 
The disk diffusion assay was completed three times (N = 3), one technical replicate per 
each biological replicate, plated at a density of OD600 = 0.5. Mean ± SEM. Two-way 
ANOVA with Sidak’s multiple comparison test, **** P < 0.0001.  
10 
µg/mL 
25 
µg/mL 
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 Identifying a strategy for HopE complementation in 
ΔhopE mutant 
Rationale:  
Since the BambL reactivity seen in HopE is lost when HopE expression is 
eliminated in the ΔhopE mutant, this is a phenotype that can now be verified via 
complementation. The best method to date for performing complementation in H. pylori 
is through chromosomal integration using suicide plasmids. While making the plan to 
perform complementation, it was noticed that the suicide plasmids available in the lab 
containing the full HopE gene had the same antibiotic selection cassette downstream of 
HopE as the ΔhopE mutants (which were generated by disrupting the gene with a CAT 
cassette). This is because they were originally created for integration of the glycosylation 
point mutants of HopE in a WT strain. Thus, the antibiotic selection cassette would have 
to be swapped to a kanamycin selection cassette in order to correctly screen for 
transformants that had successfully incorporated the full hopE gene. However, swapping 
the plasmids for a kanamycin cassette was more time consuming and did not fit into the 
timeline of the project, thus it was not possible to complete this complementation in the 
remaining time. 
 Instead of performing the full complementation, we tested if the HopE plasmid 
complementation constructs obtained from previous lab mates would express the HopE 
protein once transformed into the VJ WT strain. The lab has produced two plasmids 
containing the full hopE gene. One is plasmid pMK35 from Maryam Khodai-Kalaki 
(MK) that contains no His-tag but has a CAT cassette while the other is from Brandon 
Oickle (BO) and contains a CAT cassette and a His-tag attached to the hopE gene. To 
note, neither plasmid constructs contain a promoter region in front of the hopE gene. 
Both are promoter-less genes that, once recombined in the chromosome in the hopE 
locus, should allow expression of HopE from its endogenous promoter as per design.  
 Both plasmids were transformed separately into the VJ WT strain in an effort to 
confirm that one of these constructs can be successfully incorporated into VJ WT and 
produce functional HopE protein. The production and location of the HopE protein would 
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be assessed by Western blotting with anti-HopE and anti-His using the OM samples of 
the two clones. If HopE is successfully expressed and observed in the Western blots, then 
the process of swapping the CAT cassette for the kanamycin cassette and completing the 
complementation can be undertaken in the future. 
Result:  
 Transformation of the hopE genes followed by the CAT cassette with or without 
the His tag was successful (Figure 22). Two clones were chosen for downstream analysis, 
pMK35 706-His-less clone #1 and BO 706-His-CAT clone #5. The OMs of both clones 
were extracted, and Western blotting was performed. 
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Figure 22. Generation of the hopE + CAT strains in VJ WT. 
A) The hopE-His-CAT integration sequence showing the location of each possible primer 
available to use for PCR analysis. B) The location of the primers used to check the 
integration of the correct sequence is shown in the schematic above the gel result. 
Presence of the chloramphenical (CAT) resistance cassette and absence/presence of the 
His tag was verified by the increase in product size. HopE = HP0706. L = molecular 
weight standards. 
 
 
B 
A 
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Analysis of the new OM sample preparations of pMK35 706-His-less and BO 
706-His-CAT by Western blot using anti-HopE antibodies show that background signal 
is observed in the lanes for these samples at a level similar to the ΔhopE mutant (Figure 
23). As these plasmid constructs were transformed into VJ WT which has full HopE 
protein expression, shown on the Western blot in Figure 18, this absence of HopE 
expression indicates that the sequence of interest integrated into the correct location and 
subsequently eliminated the existing HopE expression. Through sequence analysis of the 
PCR product amplified using primers that span both upstream and downstream of the 
region containing the hopE and CAT genes (706Tag2 and 706Tag9), the sequence of 
hopE and the CAT cassette appear normal with no disruptions in their genes. However, 
the next step in this project would be to use primers that are located outside the 
recombination region and lie within the chromosomal DNA, such as 706Tag11 and 
706Tag12. The resulting sequencing of these PCR products would provide information 
about the genes upstream and downstream of the recombination junction and whether 
they were affected in some that could give a reason for the loss of HopE. 
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Figure 23. Analysis of HopE expression with Ponceau S staining anti-HopE Western 
blotting. 
Western blot of OM samples run on 4-20% precast gradient gels. Ponceau S stain on the 
right. OM samples were loaded onto the gel in two concentrations, the lower and higher 
one. Loadings for each sample was defined by previous analysis with Coomassie staining 
after OM samples were prepared. The red arrow indicates the location of HopE. The 
enhanced section of interest in the blot is shown below. M = molecular weight markers. 
 
  
77 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Discussion 
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4 Discussion 
 New anti-HopE antibodies successfully detect the HopE 
protein 
 Prior to the onset of my research into HopE glycosylation, there were no 
commercially available anti-HopE antibodies. My predecessors who had worked on this 
project had established the possibility that HopE might be glycosylated by Lewis Y using 
MS analysis and Western blotting. To connect the Lewis Y reactivity to HopE, custom-
made anti-HopE antibodies were ordered using a predicted extracellular peptide of HopE 
with the amino acid sequence of GYKKFFQFKSLDMTS.  
 After obtaining the sera of two HopE immunized rabbits and determining the final 
ELISA results, rabbit #2’s antibody sera was used as it had the higher antibody titer 
(Figure 6). However, there were several bleeds that were obtained during different 
timepoints within the immunization schedule of the rabbits. Thus, determining which 
bleed to use for successful detection of HopE was the priority. Using a step-wise gel with 
decreasing acrylamide concentration and extracting the outer membrane (OM) of the WT 
and hopE knockout strains using differential solubilization with N-laurylsarcosine, it was 
observed that all bleeds efficiently detected HopE. Using the Western blot (Figure 6) and 
the ELISA titer data, the final (fourth) bleed of rabbit #2 was utilized at a concentration 
of 1/200 for future experiments. 
 The use of the step-wise gels, while appropriate for ascertaining the working anti-
HopE antibody concentration as seen in Figure 7, was not efficient at resolving the HopE 
protein from other proteins/LPS bands that were reacting to Lewis Y and co-localizing to 
the same area as HopE. After multiple attempts to further resolve HopE from non-HopE 
Lewis Y-reactive proteins/LPS bands in these step-wise gels, it was decided that gradient 
gels may be the best solution for this recurring issue. Thus, precast gradient gels (4-20%) 
were purchased from BioRad. In Figure 7, the results obtained by the precast gels can be 
seen. The gradient gels could effectively condense and resolve the proteins and LPS into 
distinct bands, allowing for greater protein comparability between lanes within the same 
blot and within different blots. The use of commercially produced gradient gels also 
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allowed for highly reproducible and standardized blots, with proteins running to the same 
location every single time.  
 
 HopE glycosylation in Helicobacter pylori 
 With the discovery of a ~31 kb protein that reacted to anti-Lewis Y in our lab, MS 
analysis suggested that the protein was possibly HopE. However, with the acquisition of 
working anti-HopE antibodies, this idea could be verified for certain. To aid in the 
identification of HopE as a glycoprotein, the double knockout mutant ΔhopE/ΔwaaL was 
successfully generated to observe the HopE protein without interfering LPS structures in 
both Western blots and functional assays. Nevertheless, it was important to consider that 
this ΔhopE/ΔwaaL mutant does have the potential to abrogate glycosylation if WaaL 
serves as the oligosaccharide transferase (OST). If WaaL was not the OST, the synthesis 
of O-units would still be preserved and could be transferred onto HopE by the true OST, 
such as HP0946. 
 From examining the results of the anti-HopE and anti-Lewis Y blots (Figure 14), 
it is evident that the reactivity of the Lewis Y antibodies in the area of HopE does not 
change in response to the loss of the HopE protein in the ΔhopE mutants (in WT or in the 
ΔwaaL background strains). This is likely because HopE is not glycosylated by Lewis Y. 
However, one caveat to mention is that as there appears to be a strongly reacting band to 
Lewis Y in the same area as where the HopE localizes, and this might mask the loss of 
Lewis Y signal if HopE was glycosylated with Lewis Y. It is likely, according to MS 
data, that HopE would only have one unit of Lewis Y motif, thus it might not be easily 
detected by the Lewis Y antibody so its loss in the ΔhopE mutants would not be visible 
when compared to the other proteins/LPS also reacting in that area. Objective 2 of the 
hypothesis was to determine if the HP0946 protein is the Lewis oligosaccharide 
transferase (OST) for HopE glycosylation. These series of blots determined that HP0946 
is not the OST for HopE Lewis Y glycosylation. This is evidenced by the lack of any 
changes to the Lewis Y reactivity in the HopE area for the Δ946 mutant.  
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Conversely, the BambL blots (Figure 17), that detect fucosylated epitopes which 
include Lewis Y but also non-Lewis Y epitopes, showed the opposite. When HopE 
expression was eliminated, it appeared that BambL reactivity was also absent. Thus, there 
is evidence that HopE may be glycosylated by a non-Lewis Y glycan. However, like the 
anti-Lewis Y blot illustrated, the Δ946 mutant still had BambL reactivity in the HopE 
area, meaning HP0946 is not an OST for the HopE protein. With this result, it is 
important to try to elucidate both the identity of the non-Lewis Y glycan and the identity 
of the OST responsible for transferring the glycan to HopE. 
To note, Figures 15, 16, and 18 show the results of testing for non-specificity 
from the secondary antibody. The results illustrate that although all blots, especially the 
anti-HopE blot (Figure 14), have multiple bands, these bands are not due to non-specific 
binding by the secondary antibody. The multiple bands seen on Figures 14 and 17 when 
using both primary and secondary antibodies/lectin are likely due to the antibody/lectin 
reacting to proteins/LPS that contain the epitopes of interest. 
Additionally, eliminating HP0946 expression causes the generation of higher 
molecular weight bands that are reactive to both Lewis Y and BambL. This is evidenced 
when comparing the Proteinase K treated samples in the anti-Lewis Y and BambL 
Western blot in Figure 13 to the blots in Figure 14 and 17. Currently, there are a couple 
unknown aspects of this discovery, such as whether these bands are LPS or proteins and 
the function of HP0946. However, since HP0946 is localized to the inner membrane, it is 
entirely possible that eliminating this protein may indeed affect the LPS synthesis 
pathway as most of the proteins involved in that pathway are also found within the inner 
membrane. Again, a complete answer for this phenotype is yet forthcoming.  
The discovery of an outer membrane protein with an unknown fucose-containing 
glycan signifies the importance of molecular mimicry in H. pylori. Although it is not 
Lewis Y, as a fucose-containing glycan it may still be Lewis X, Lewis a or Lewis b, 
which are human blood group antigens73.  
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 Variations in LPS pattern for different H. pylori strains 
To achieve further observation of the LPS pattern in the working strains, PK 
treated OM samples were visualized using the silver staining method. Treating the OM 
samples with PK should effectively digest the protein content and leave the LPS 
molecules intact. In the silver stain of Figure 12, there is a discrepancy in the LPS pattern 
when comparing the WTs and ΔwaaL mutant and ΔhopE/ΔwaaL double knockout 
mutant to the ΔhopE and Δ946 mutants. The WTs and ΔwaaL mutant and ΔhopE/ΔwaaL 
double knockout mutant do not have the higher silver-reactive bands (~31 – 40 kDa, 
indicated by a green bracket) that are seen in the ΔhopE and Δ946 mutants. Initially, it 
was assumed that this was evidence for a variation of the LPS between the WTs and the 
ΔhopE and Δ946 mutants. The results of the waaL and ΔhopE/ΔwaaL mutants are as 
expected since these strains do not have the O-antigen ligase therefore they would not 
have a full LPS pattern. Additionally, it was confirmed that the lanes containing OM PK-
treated samples from the ΔhopE and Δ946 mutants do have higher silver-reactive bands 
that are likely LPS and not proteins. This was verified by the concurrently performed 
Coomassie stain, which does not show those bands, indicating they were not protein 
bands that were PK resistant.  
However, the WT strains also had less lipid-A core concentrations in the Figure 
12 silver stain, implying that although every effort was taken to aim for equal loading, the 
WT samples may not have been loaded as strongly as the other strains. Thus, another 
silver stain was conducted with freshly extracted WT OM samples and the new OM 
samples of ΔhopE/Δ946 mutant. As Figure 13 clearly demonstrates, despite our best 
efforts to ensure equal loading in Figure 12, there was a loading issue for the WTs that 
resulted in the low visibility of the higher LPS molecules via silver stain. In fact, the best 
way to visualize the higher LPS molecules was to cut out that area and re-stain with 
silver.  
This variation in O-antigen expression between each OM extraction could also 
play a role in influencing each individual antibiotic assay, making it very important to 
have replicates of each assay, regardless of how reproducible the tests reportedly are 
(such as the Etest). To summarize, both silver staining and Coomassie results indicate 
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that the LPS molecules seen in the 31-40 kDa range are present in all the strains and do 
not change depending on a specific mutant. 
 
  Immunoprecipitation of HopE to identify HopE 
glycosylation 
 To definitively determine the presence/absence of HopE glycosylation, 
production of cleaner Western blots without interfering proteins or LPS was attempted. 
Therefore, purification of HopE through immunoprecipitation was required. However, 
the protein HopE is part of the insoluble outer membrane section of HP, rendering the 
outcome of conventional immunoprecipitation assays to purify HopE uncertain. 
 In an attempt to make the insoluble OM portion more soluble and subsequently 
release the HopE protein into the soluble supernatant, the OM sample of VJ WT was 
subjected to lysing via Triton X-100, a non-ionic detergent. As the effectiveness of this 
attempt remained unclear, the OM sample was lysed twice, first with 0.2% Triton X-100 
and diluted by half in buffer solution and the second time with 1% Triton X-100 and 
diluted ten-fold. However, only the first lysis was subjected to immunoprecipitation since 
it would have the higher concentration of soluble HopE protein.  
After running all the immunoprecipitation fractions on an anti-HopE Western blot 
(Figure 19), it was evident that although the blot was cleaner and contained less proteins, 
the HopE protein had not bound well to the protein G-antibody linked beads. The reason 
for this is likely due to the pH of the buffer containing dimethyl pimelimidate (DMP), the 
cross-linking reagent, being below pH 8. If the pH of the solution falls below 8, or rises 
above 9, the cross-linking efficiency of DMP is greatly reduced74. However, the pH of 
the solution was 7.42 in response to the isoelectric point of HopE being 8.86, since the 
efficient functioning of the sodium phosphate buffer requires its pH to be at least 0.5 pH 
units away from the isoelectric point of the HopE protein. Thus, the DMP was not 
effectively cross-linking the antibody to the protein G beads, resulting in a weak bond 
that could easily dissociate and elute early the antibody and the HopE protein. One future 
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direction to obtain better immunoprecipitation results would be to increase the pH of the 
buffer solution to around pH 8.3; this should allow DMP to work effectively. Regardless 
of this low cross-linking efficiency, immunoprecipitation was still a success as it reduced 
non-HopE protein and allowed for more targeted Western blotting assays to be 
performed. 
After confirming the presence of the HopE proteins in the immunoprecipitation 
fractions using anti-HopE antibodies, the membrane was re-blotted with anti-Lewis Y to 
determine the potential for Lewis Y glycosylation. As in previous anti-Lewis Y Western 
blots shown in this thesis, the cleaner Western blot showed that Lewis Y was not reactive 
to HopE (Figure 19). This is the best proof that HopE is not glycosylated by Lewis Y. 
However, the reactivity of BambL to HopE seen in Figure 17 indicates that while HopE 
may not contain the Lewis Y glycan, it does appear to be glycosylated by a non-Lewis Y 
glycan that contains fucose. Previous research conducted by other labs has shown that HP 
NCTC 11637 also contains H-type O-antigens75 and BambL has shown to bind 
preferentially to H-type glycan compared to Lewis Y76. Thus, it is possible that the 
glycan in question is an H-type, which only contains the fucose on the terminating end of 
the O-antigen. 
The putative glycosylation of HopE aligns with porin glycosylation in previous 
literature. Currently, there are only two well-established porin glycoproteins: C. jejuni’s 
major outer membrane protein (MOMP)63 and P. aeruginosa’s OprD64. However, among 
the three porins, glycosylation occurs using differing glycans, whereby the MOMP is 
glycosylated with one galactose and three GalNAc residues, OprD contains 3 sialylated 
N-glycans and 2 sialylated O-glycans, and HopE is glycosylated with a fucose-containing 
glycan. Importantly, the glycosylation of MOMP was observed to occur at T268, which is 
in a surface exposed loop as was found in HopE. In this thesis, the role of HopE and its 
glycosylation in antibiotic resistance was studied, as porin OprD plays a role in antibiotic 
susceptibility64. As evidence shows that HopE is likely glycosylated, one future direction 
(once complementation has established HopE as a glycoprotein) could be to study the 
role of HopE’s glycosylation in other processes such as those studied in MOMP. 
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Glycosylation of this MOMP porin indicated a correlation to promoting bacteria-to-
bacteria binding, biofilm formation, and adhesion to Caco-2 cells.  
 The HopE porin likely does not play a role in antibiotic 
susceptibility 
 Previous research into other porins have implicated porins as a passage for 
antibiotics into the cell15,77, such as Escherichia coli’s OmpC78, Acinetobacter 
baumannii’s OmpA79, and Vibrio cholerae’s OmpU80. Additionally, it was also shown 
that sialylation of the porin OprD of Pseudomonas aeruginosa resulted in decreased 
uptake of β-lactam antibiotics through this porin64. Thus, the possibility that HopE and its 
putative glycosylation play a role in antibiotic resistance was explored via the use of 
several antibiotics and multiple antibiotic sensitivity assays.  
 Table 3 lists the various types of antibiotics used, each with a different 
mechanism of action to target various processes within the bacterial cell. These three 
specific antibiotics were also chosen due to their clinical relevance, as they are all used in 
triple and quadruple therapy treatments to combat HP infection10. Using these antibiotics, 
different antibiotic sensitivity assays were employed, including spot plating, gradient agar 
plate method, E-tests and disk diffusion assays. Each assay was meant to complement 
one another; however, not all the assays lead to reproducible results. 
 The spot plating method is a long exposure test conducted by incorporating the 
test antibiotic into blood agar media and observing the growth of the bacteria. As we did 
not know which specific concentration of each antibiotic would be effective at 
differentiating the strains, three different concentrations for all antibiotics used were 
tested (data not shown). To note, the strains were grown on solid media instead of a broth 
because HP does not grow well in broth. HP simply survives, which is not adequate for 
antibiotic sensitivity testing as several antibiotics target peptidoglycan growth and protein 
synthesis, so the bacteria need to be actively growing. Once the proper optical density 
was achieved, the cultures were serially diluted 10-fold for 8 dilutions and spot-plated on 
the antibiotic-incorporated plates. Two strains were tested on one plate with one 
antibiotic at a specific concentration. Thus, a single strain was tested on three 
85 
 
concentrations of one antibiotic, plus a control containing just the background antibiotics 
usually used and no test antibiotic. Once the bacterial colonies had grown well enough to 
count them, the CFU/mL was calculated and compared among strains. Results from 
multiple trials of this assay proved to be inconsistent and the colonies were hard to count 
accurately. This assay was also not as high throughput as was required to test the large 
number of strains that were studied within this thesis; thus, the spot plating method was 
set aside.    
 As another method of testing antibiotic sensitivity, the strains were grown on 
antibiotic gradients via the gradient agar plate method (data not shown). In this assay, the 
plates are manually created and the initial antibiotic used was clarithromycin, as it was 
the most promising antibiotic that gave differences between the strains in the spot plating 
method. The plates are laid out on a slant and the agar containing the test antibiotic is 
poured into the plate. After this layer cooled down, that plates were placed back on level 
surface and agar with only background antibiotics were poured. Once cooled, the plates 
were flipped upside down and the antibiotics began to diffuse, thus establishing a 
gradient of antibiotic concentration. According to literature, as antibiotics can diffuse in 
the plates, the plates should be used not too long after the 12 hour mark81. The HP strains 
are then spread via sterile glass beads on the gradient plates and the control plate (no 
gradient, no test antibiotic) and incubated for 16 hours. Results of this method showed 
that there were no discernible changes in growth density across the gradient plates. It was 
decided that this method may not be the best assay for a slow growing organism, as the 
antibiotic gradient may be lost before it can successfully affect HP growth, which would 
especially be a problem if the antibiotic was bacteriostatic. This assay was abandoned 
after two trials. 
 Following the failure of the spot plating and gradient agar method, Etest strips 
were purchased for levofloxacin and amoxicillin. Etest strips are considered the gold 
standard for testing the response of bacteria to antibiotics in clinical laboratories. The 
strips also generate highly reproducible results, are easy to use, and are high throughput. 
At the time, commercial strips for clarithromycin were unavailable so the disk diffusion 
assay was implemented for this antibiotic. 
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Considering the results of the levofloxacin Etest, most strains did not react 
significantly different to each other, including the WTs and VJ ΔhopE (Table 5). This 
provides evidence that eliminating HopE expression does not cause an increase in 
susceptibility or resistance. This was further proven by the double knockout mutant 
ΔhopE/ΔwaaL, which was initially created to compare against the ΔhopE and ΔwaaL 
mutants. As the LPS O-antigen is lost in this double knockout, this loss should allow the 
antibiotics to have clearer access to the HopE porin without the steric hindrance provided 
by the LPS molecules on the outer membrane. However, it appeared that any increase in 
susceptibility that this double knockout mutant exhibits could be attributed to the 
phenotype caused by the elimination of the O-antigen ligase WaaL as can be seen in the 
single ΔwaaL. Furthermore, contrasting the longer BambL- and Lewis Y-reactive LPS 
pattern seen in the VJ ΔhopE mutant (Figures 14 and 17) with the shorter one observed in 
VJ WT also indicated that this variation in LPS does not affect the way these two strains 
interact with levofloxacin, which aligns with the silver stain gel (Figure 13) that shows no 
variation in the LPS. These results are also mirrored in the amoxicillin Etest results. 
The purpose of the ΔhopE/Δ946 mutant was to eliminate HopE expression in a 
strain that had LPS matching the LPS of the ΔhopE mutant. This was effective, and the 
LPS pattern of the ΔhopE/Δ946 mutant remained the same as its respective single 
mutants. Through the successful generation of the ΔhopE/Δ946 mutants, there is further 
evidence that eliminating HopE does not change the susceptibility of the ΔhopE/Δ946 
mutant to levofloxacin or amoxicillin compared to the single Δ946 mutant. This same 
outcome was also seen in the antibiotic sensitivity results for ΔhopE/ΔwaaL in that 
eliminating HopE didn’t affect how ΔhopE/ΔwaaL reacted to the antibiotic compared to 
the ΔwaaL mutant. 
To overcome the lack of clarithromycin Etest strips, this assay was performed by 
adding two different concentrations of clarithromycin to separate homemade disks and 
placing the disks on a lawn of bacteria, similar to the Etest. This method, while cheaper 
than the Etest strips, was slightly more time consuming and required some trial and error 
to get the right working concentrations of antibiotics to obtain readable zones of 
inhibition. However, the results of this test were very reproducible, and the method 
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allowed for higher throughput as multiple disks of different antibiotic concentrations 
could be placed on a single plate with the bacterial lawn. As Figure 21 demonstrates, 
when comparing the WTs to the Δ946¸ ΔwaaL and double knockout mutants, the results 
of this assay closely resembled those of the Etest disks and were more highly visual. 
Again, ΔhopE mutants did not vary from the WTs, similar to the Etests.  
Collectively, all these antibiotic tests show that eliminating HopE does not cause 
a significant difference when matching the mutant to its isogenic strain (be it the WT 
strain, ΔwaaL mutant, or Δ946 mutant) for either levofloxacin, amoxicillin or 
clarithromycin. HopE does not play a role in antibiotic susceptibility. Interestingly, the 
results of the disk diffusion method showed that eliminating HP0946 increased the 
susceptibility of the Δ946 strain to clarithromycin; the results were significantly different 
compared to the WT strains and similar to the ΔwaaL and the ΔhopE/ΔwaaL mutants 
which are lacking the full LPS structure. As seen in the anti-Lewis Y and BambL blots, 
the Δ946 mutant has its full LPS therefore an alternate explanation must be discovered. 
Very little is known about this protein, which has been annotated as a sodium-proton 
antiporter but never confirmed. One hypothesis is that perhaps HP0946 is involved in 
either preventing entry of antibiotics across the inner membrane or may be involved in 
extruding antibiotics back to the periplasm. 
 Working towards a functional complementation strategy 
to restore hopE expression in the ΔhopE mutant 
Through the elimination of HopE expression, it was discovered that WT strains 
contain a BambL-reactive band in the HopE protein region that is lost in the hopE 
knockout mutants, implicating the existence of HopE as a fucose-containing 
glycoprotein. To verify that this is a robust phenotype, complementation would be the 
next step of this project. However, due to the suicide plasmids with full HopE constructs 
containing the same selection cassette as the hopE mutants, swapping the selection 
cassette to kanamycin was beyond the timeline of my project. Thus, to ensure that the 
plasmids containing the full hopE gene would successfully integrate into the knockout 
mutant and allow expression of the HopE protein, these HopE promoter-less plasmids 
pMK35 706-His-less and BO 706-His-CAT were separately transformed successfully 
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into VJ WT. The purpose of the histidine tag within the clone created by BO was in an 
attempt to tag and purify the HopE protein as purification of proteins using affinity 
chromatography with nickel targeting the His tag had been proven to provide high protein 
yields and purity of over 95%82. This tag was added to the C-terminus of the protein to 
prevent its removal when the N-terminal signal sequences of the protein is cleaved during 
transport into the periplasm83. Subsequent nickel affinity chromatography did not detect 
His tagged HopE in the outer membrane fractions. It was assumed that this method for 
identifying His tagged HopE proteins was ineffective given the circumstances or that the 
His tag may prevent proper folding and OM localization of HopE. However, at the time 
of the creation of this His tagged HopE, there were no anti-HopE antibodies to confirm 
that His tagging might have altered HopE protein expression itself. 
Two of the resulting clones from each set of transformations were analyzed via 
PCR using primers that spanned the length of the gene sequence of interest (Figure 22), 
706Tag9 annealed within the integrating construct while 706Tag2 annealed to the 
chromosomal DNA downstream of the region of recombination. The sequencing data 
indicated that both the hopE gene and the CAT cassette gene had successfully 
incorporated into the VJ WT genome without mutations and that the sequence inserted 
into the correct area. Therefore, the outer membranes were extracted from one clone from 
each transformation and subjected to anti-HopE Western blotting. 
Comparing the WT, ΔhopE, pMK35 706-His-less and BO 706-His-CAT samples 
to each other indicated that incorporation of the new hopE gene sequence into the VJ WT 
eliminated the expression of HopE entirely, similar to the ΔhopE mutant. This 
elimination also indirectly confirmed that the plasmids had recombined correctly and 
inserted the sequence into the right area. One of the reasons for this lack of HopE protein 
expression could be due to the His tag attached to the HopE protein. Perhaps the His tag 
prevented proper folding of the HopE protein, resulting in the protein being degraded and 
prevented from being exported to the outer membrane. Conversely, the pMK35 706-His-
less clone should not have a functional His tag and sequence analysis showed that the His 
sequence is still there with a stop codon placed before it to prevent its translation. Lack of 
HopE expression in this clone indicated that either the stop codon and His sequence still 
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resulted in disrupting HopE expression, perhaps because of mRNA instability, or 
something else unrelated to the His tag DNA sequence was the cause of the loss of 
protein expression. It may be possible that integration of this sequence causes gene 
disruptions either upstream or downstream of the integration area. 
 Summary and future directions 
To re-iterate, the objectives of this project were: 
1) Optimize the detection of HopE using anti-HopE antibodies to determine whether 
HopE is glycosylated, via anti-Lewis Western blotting.  
2) Investigate the role of the Lewis oligosaccharide transferase HP0946 in potential HopE 
glycosylation and determine its connection to LPS synthesis.  
3) Elucidate the functional impact of HopE and its putative Lewis glycosylation in regard 
to antibiotic resistance/susceptibility. 
 To highlight objective 1, this study demonstrated the presence of HopE as a novel 
glycoprotein that is glycosylated by a currently unknown glycan containing fucose. This 
was done in part through the successful optimization of the anti-HopE antibodies, 
regardless of the serum’s propensity to cross-react with non-HopE OM proteins with 
similar epitopes to the porin. Although initially it was thought that the glycan was Lewis 
Y, after comparing the anti-Lewis Y blots with anti-HopE, it became clear that this was 
not the case. Through the use of the BambL lectin, it was determined that the glycan did 
contain a fucose (like Lewis Y) but was another as yet unidentified glycan.  
 As a result, a future direction of this study is to further characterize this HopE 
glycoprotein and determine the glycan with which it is glycosylated. The next step in this 
characterization would be to develop strategies to specifically purify for HopE and other 
glycoprotein candidates that react to BambL. In this case, affinity for the BambL lectins 
can be utilized to purify for glycoprotein candidates from the unmodified proteins. For 
this method, BambL lectin could be coupled to a matrix containing sepharose. 
Subsequently, the BambL lectin can be used to purify the fucose-modified glycoproteins 
90 
 
(including HopE) via affinity chromatography. Once purified by this method, the 
glycoprotein candidates can be sent for MS analysis for identification of the proteins and 
the glycan itself. 
 Nevertheless, the results of this thesis also indicate that contrary to our hypothesis 
for objective 2, HP0946 is not the OST that glycosylates HopE as the HopE band is still 
present and BambL-reactive in the Δ946 mutant during Western blotting. Furthermore, 
this work also eliminates the possibility that the O-antigen ligase may play the role of 
OST for HopE as the same HopE band is BambL-reactive in the ΔwaaL mutant. We 
showed that HopE is glycosylated with a fucose-containing glycan, which does not 
eliminate non-Lewis Y antigens (such as Lewis X, a, or b) which were presumed to be 
exclusively associated with the LPS. Thus, it is still possible that glycosylation in HP is 
linked to the LPS synthesis pathway. Further studies are needed to determine the precise 
relationship between the two processes, whereby the impetus lies in identifying the OST 
for this glycosylation of HopE. 
 Moreover, the deletion of HP0946 expression also causes the increased generation 
of LPS/protein bands reactive to both Lewis Y and BambL. As an inner membrane 
protein, the elimination of HP0946 would likely also affect the LPS synthesis pathway as 
most enzymes related to this pathway also exist in the inner membrane.  
 To ensure that lack of BambL-reactive glycoprotein in the ΔhopE mutants and the 
antibiotic susceptibility in the Δ946 mutant are true phenotypes, a future direction would 
be to facilitate the successful complementation of both mutants. The complementation of 
HopE was initiated in this thesis with two suicide plasmids, one containing the HopE 
with a His tag and the other without it. However, clones from both transformations 
showed no expression of HopE when subjected to an anti-HopE blot. A future direction 
for this method would be to use primers that span entirely outside the recombination area 
and within the chromosomal DNA, such as 706Tag11 and 706Tag12. Sequencing the 
resulting PCR product could indicate if the genes upstream and downstream of the 
recombination junction were affected in some way, providing a reason for the loss of 
HopE production. Additionally, another attempt can be conducted on transforming VJ 
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WT using a suicide plasmid without the DNA sequence for the His tag at all. The results 
of this attempt would determine if the His tag DNA sequence was the reason for the loss 
of the protein expression or if the act of recombination resulted in an unforeseen mutation 
elsewhere in the chromosome that affected HopE production. 
 By successfully creating a plasmid that will subsequently be transformed into the 
recipient strain ΔhopE and express HopE, this would be the crucial step in working 
towards complementation of HopE. Once this step is completed and the correct antibiotic 
cassettes are being utilized, the VJ ΔhopE mutant can be complemented and the 
glycosylation of HopE can be confirmed. Similarly, a plasmid vector containing the full 
HP0946 gene construct should also be created and transformed into the Δ946 recipient 
strain for verification of the LPS variation and antibiotic susceptibility phenotypes. 
 Currently, the functional impact of neither HopE nor its putative glycosylation has 
been elucidated, as objective 3 had suggested. Antibiotic testing with three different 
substances of varying characteristics (levofloxacin, amoxicillin and clarithromycin) all 
present the same results, demonstrating that HopE does not play a discernible role in 
antibiotic susceptibility. However, a novel discovery indicates that HP0946 may have a 
link to antibiotic sensitivity since eliminating HP0946 causes an increase in 
clarithromycin susceptibility for the Δ946 and ΔhopE/Δ946 mutants. One explanation put 
forth for this involved HP0946 facilitating the prevention of entry of antibiotics across 
the inner membrane or extruding the antibiotic back to the periplasm. Therefore, the 
future direction for this aspect of the project would be to complement the Δ946 mutant 
and test with the same antibiotics to ensure this phenotype is a result of the loss of 
HP0946. Once this is established, a further examination into the mechanism of HP0946 
in relation to antibiotics must follow.  
 In summary, we showed that HopE is glycosylated with a fucose-containing 
glycan, and it may have a link to LPS synthesis which will be corroborated once the 
complementation has been completed. HP0946 was observed to not be the OST of 
interest, and neither was WaaL. We also show that HP0946’s elimination appears to 
result in a generation of more LPS or glycoproteins that are BambL and Lewis Y 
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reactive. HP0946 also may be linked to antibiotic interaction and may increase 
susceptibility to clarithromycin when its protein expression is lost. These discoveries 
provide new insight into the mechanisms of H. pylori and the tools it uses to evade the 
host immune response and develop immunity to current antibiotic treatments. 
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